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Abstract 
 
Purpose 
To demonstrate the impact of the new legislation of pharmacovigilance in the real-world 
context by the presentation of practical examples. 
 
Methods 
Critical analysis of the current pharmacovigilance legislation, as well as guidelines and 
recommendations from the European Medicines Agency (EMA). 
 
Results 
It will be presented a fictitious company risk management system, with its description of 
the risk management system through the Pharmacovigilance System Master File 
presentation and a concrete example of a Risk Management Plan of the medicinal 
product Isotretinoin with detailed implementation proposals of risk minimization 
measures, in line with the recommendations of the Pharmacovigilance Risk Assessment 
Committee (PRAC) for the recent referral procedure of retinoids. 
 
Discussion/Conclusions 
The new European Legislation in Pharmacovigilance and, consequently, the new 
regulatory requirements have increased the workload and complexity of 
pharmacovigilance. The focus of the pharmacovigilance system became a proactive, risk 
proportionate and patient-centered approach, with high level of transparency and 
engagement of civil society.  This approach brings to fulfil previously unmet medical 
needs and reducing the burden of adverse drugs reactions by promoting the safeguard 
public health. 
 
Keywords: Pharmacovigilance; Legislation; Pharmacovigilance System Master File; 
Risk management plan; Risk minimization measures, PRAC, Referral Procedure; 
Isotretinoin.
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Resumo 
 
Objetivo 
Demonstrar o impacto da nova legislação de farmacovigilância no contexto do mundo 
real através da apresentação de exemplos práticos. 
 
Métodos 
Análise crítica da atual legislação de farmacovigilância, bem como guidelines e 
recomendações da Agência Europeia de Medicamentos (EMA). 
 
Resultados 
Irá ser apresentado um sistema de gestão de risco de uma empresa fictícia, com a sua 
descrição do sistema de gestão de riscos através da apresentação do dossier do 
Sistema de Farmacovigilância e de um exemplo concreto de um Plano de Gestão de 
Risco do medicamento Isotretinoína, com propostas detalhadas de implementação de 
medidas de minimização de riscos,.em consonância com as recomendações do Comité 
de Avaliação do Risco de Farmacovigilância (PRAC) em virtude do procedimento de 
arbitragem a acontecer com os retinóindes. 
 
Discussão/Conclusões 
A nova Legislação Europeia em Farmacovigilância e, consequentemente, os novos 
requisitos regulamentares aumentaram a carga de trabalho e a complexidade da 
farmacovigilância. O foco do sistema de farmacovigilância tornou-se uma abordagem 
pró-ativa, proporcional ao risco e centrada no paciente, com alto nível de transparência 
e envolvimento da sociedade civil. Esta abordagem permite satisfazer as necessidades 
médicas anteriormente não conhecidas e reduzir a carga de reações adversas a 
medicamentos, promovendo assim a salvaguarda da saúde pública. 
 
Keywords: Farmacovigilância, Legislação, Dossiê Principal de Farmacovigilância; 
Plano de Gestão de Risco, Medidas de Minimização do Risco, PRAC, Procedimento de 
Arbitragem, Isotretinoína. 
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1.  Introduction 
 
Pharmacovigilance is the science and activities relating to the detection, assessment, 
understanding and prevention of adverse effects or any other medicine-related problem. 
The European Medicines Agency (EMA) coordinates the European Union (EU) 
pharmacovigilance system and operates services and processes to support 
pharmacovigilance in the EU [2].  
 
Before a medicine is authorised for use, evidence of its safety and efficacy is limited to 
the results of clinical trials, where patients are selected carefully and followed up very 
closely under controlled conditions. This means that at the time of a medicine’s 
authorisation it has been tested in a relatively small number of selected patients for a 
limited length of time [2]. 
 
In the post-marketing period, the product can be subject of use in settings largely 
different from the clinical trials before approval. In other words, a much larger population 
with a different range of co-morbidities or polymedicated may be exposed in a relatively 
short timeframe [2].  
 
The safety information about the product is likely to change over time through its 
expanded use, specifically in terms of patient pool variations and the number of exposed 
population. Thus, market vigilance systems must be implemented and maintained after 
a drug has been launched in the market to detect safety issues that were not evident 
prior to commercialization [3].  
 
Furthermore, the pharmacovigilance systems to be effective require the participation and 
cooperation of the patients, healthcare professionals, the pharmaceutical industry as well 
as the regulators, on the way that critical safety information can be identified and rapidly 
acted. In some instances, this has resulted in the withdrawal or restriction of drugs due 
to safety concerns that only emerged post-marketing [1,2]. 
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1.1. Pharmacovigilance 
 
According to the definition of World Health Organization (WHO), pharmacovigilance is 
the science that comprises activities relating to the detection, assessment, 
understanding and prevention of adverse effects or any other possible drug related 
problem [3]. 
 
The aforementioned definition comprehends the knowledge and all activities required for 
the safe and effective use of the medicinal products. 
 
The European Medicines Agency (EMA) coordinates the European Union 
(EU) pharmacovigilance system and operates services and processes to 
support pharmacovigilance in the EU [2]. 
 
The specific aims of pharmacovigilance are to improve patient care and safety in relation 
to the use of medicines and all medical and paramedical interventions, improve public 
health and safety in relation to the use of medicines, contribute to the assessment of 
benefit, harm, effectiveness and risk of medicines, encouraging their safe, rational and 
more effective (including cost-effective) use, and promote understanding, education and 
clinical training in pharmacovigilance and its effective communication to the public [4]. 
 
There are several tools available for the monitoring of safety of medicinal products such 
as spontaneous reporting of Adverse Drug Reactions (ADRs), qualitative and 
quantitative signal detection, Periodic Safety Update Reports (PSURs), Risk 
Management Plans (RMPs) and also Post-authorisation Safety Studies (PASS) [5,6]. 
 
Spontaneous reporting of Adverse Drug Reactions (ADRs) 
The spontaneous reports of adverse drug reactions are an important source for 
pharmacovigilance data, on which signal detection activities can be performed. 
Signal detection may use both qualitative and quantitative approaches, such as manual 
review of individual cases and data mining tools. These tools are associated with several 
challenges and controversies [5,6]. Quantitative signal detection methods are based on 
statistical analysis and become more reliable when based on more data [7,8,9,10]. 
 
 
Qualitative and quantitative signal detection 
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Qualitative signal detection methods based on the review of cases may be less impacted 
by lower numbers but is more time consuming and requires trained specialists able to 
identify a trigger case, and maybe challenging in distinguishing an ADR from the disease 
being treated [10]. 
 
Periodic Safety Update Reports (PSURs) 
PSURs are pharmacovigilance documents intended to provide a periodic evaluation of 
the risk-benefit balance of a medicinal product for submission by companies at defined 
time points during the post-authorisation phase [2].  
 
Risk Management Plans (RMPs) 
The RMP is the main planning instrument aimed to facilitate a more proactive approach 
in filling knowledge gaps through early planning of pharmacovigilance activities and it 
should ensure a feasible and risk-proportionate pharmacovigilance planning. Developing 
a RMP is a challenging task in view of the limited knowledge of the benefit risk profile at 
the time of marketing authorization. Nevertheless, it is a legal requirement and all 
companies must fulfil this obligation [11]. 
 
Post-Authorisation Safety Studies (PASS) 
PASS are a tool to collect additional pharmacovigilance data [2]. These studies may 
have different approaches and designs. In order to overcome the related challenges, to 
implement these tools the European Commission has enhanced the importance of 
pharmacovigilance by developing a new legislation which includes a wide range of 
measures [12]. 
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1.2. The importance of monitoring the safe use of medicines 
 
The goal of monitoring and collecting data on ADRs is the rationalization of 
pharmacotherapy in order to use the most effective medicine with the least ADR upon 
the establishment of the proper diagnosis [13]. 
 
ADRs may be observed both during preclinical and clinical trials. Information on ADRs 
collected during these phases of drug development cannot predict a possible adverse 
event that may take place only after the placing of the medicinal product on the market. 
Among the main reasons are the fact that animal studies are insufficient to predict the 
safety of medicines in humans, the fact that in clinical trials only a limited number of 
selected patients is included, the conditions of administration of the medicine are 
different from those in normal clinical practice, the duration of trials is limited, and that 
data on rare serious adverse events, toxic effects of chronic treatment, the use of a 
medicine in specific categories of patients (children, the elderly, pregnant women) or 
interactions with other medicines are often incomplete or not available [13]. 
 
The most important source of new information on the unknown effects of medicines 
before its registration represents the fourth phase of clinical testing or monitoring of 
medicines. It starts after the registration is obtained and indicates that the medicine is in 
widespread, general use. This phase lasts indefinitely. During this period both harmful 
and beneficial unknown aspects of the drug are revealed. After placing a medicine on 
the market, manufacturers are obliged to monitor its safety, although this does not 
necessarily imply the organization of prospective studies about its ADRs [13]. 
 
Monitoring the safety of medicines on the market is a valuable tool for detecting ADRs 
that are the result of counterfeiting or inadequate quality of a medicine [13]. 
An organized and permanent monitoring of the effects of medicines after obtaining 
marketing authorisation is necessary to recognize and prevent ADRs on time [13]. 
 
Decision of withdrawal of medicines from the market due to the unfavorable ratio of 
benefits and risks is based on data collected by spontaneous reporting of adverse 
reactions [13]. 
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1.3. History/background of Pharmacovigilance  
 
Before 1950, the importance of post-marketing surveillance for new medicines was not 
considered as a commitment that should integrate each physician, patients and 
lawmakers as nowadays [14]. 
 
In 1962, the disaster of phocomelia associated with thalidomide was an eye-opening 
situation for the world about the importance of drug surveillance in clinical practice. 
Thalidomide was commercialized in several countries under many trade names and 
indicated for several therapeutic conditions. Phocomelia associated with thalidomide 
awoke the interest of all medical community and the governments around the world. For 
instance, the United Kingdom started a spontaneous reporting called the “yellow card” 
scheme. Similar activities were started in other countries such as Canada, Norway, 
Sweden, and Denmark in order to strengthen the patients’ safety and public health [14]. 
 
In 1968 the World Health Organization established an international Pharmacovigilance 
program “Program on International Drug Monitoring” that has been executed since 1978 
by the international center for Pharmacovigilance that centralizes data about adverse 
effects collected by national Pharmacovigilance centers [14]. 
 
In the early 1970s another drug safety disaster occurred. This was the multi-system 
disorder known as the oculo-mucoctaneous syndrome caused by practolol (Eraldin) – a 
cardioselective betablocker used to treat angina and hypertension. The fundamental 
problem in this instance was a failure of timely identification despite having an early 
warning system in place [14]. 
 
The overriding message from Practolol was that spontaneous ADR reporting alone is 
insufficient as a means of studying pos-marketing safety. Thus, in the late 1970s various 
schemes designed to closely monitor the introduction of new drugs were suggested, but 
most of them were not implemented [14]. 
 
The Belgian Centre for Pharmacovigilance for medicines for Human use (BCPH) started 
its activities in 1976 after being recognized by the WHO. Since then the BCPH has been 
centralizing all reports of adverse effects concerning authorized medicines [14]. 
 
In 2001 the European Medicines Agency (EMA) launched EudraVigilance, a web-based 
information system designed to manage information on safety reports. Since then, it has 
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extended the system to allow commercial and non-commercial sponsors to report 
suspected unexpected serious adverse reactions (SUSARs) occurring during clinical 
trials electronically [15]. 
 
In 2002, more than 65 countries had their own Pharmacovigilance centers. 
 
The International Conference on Harmonization (ICH) is a more formal group than 
Council for International Organizations of Medical Sciences (CIOMS) with a wider remit 
for harmonization across the drug development process. The main purpose is to 
harmonize existing guidelines from EU, USA and Japan, related to development and 
registration of medicines. 
In relation to Pharmacovigilance, the key ICH guidelines and dates at which they were 
implemented are [16]: 
-  E2A: Definitions and Standards for Expedited Reporting (1994)  
- E2B: Data elements for Electronic transmission of Individual Case Safety Reports 
(1997)  
-  E2C: Periodic Safety Update Reports for Marketed Drugs (1996)  
-  E2D: Post-approval Safety Data Management (2003)  
-  E2E: Pharmacovigilance Planning (2005)  
The new Pharmacovigilance legislation in 2010/2012 brought significant changes related 
to the existing Pharmacovigilance requirements. More post-authorization safety and 
efficacy studies, a new Pharmacovigilance Risk Assessment Committee (PRAC) - the 
committee at the European Medicines Agency that is responsible for assessing and 
monitoring safety issues for human medicines, at the European Medicines Agency 
(EMA) and a broader reporting of side-effects by patients are among the new measures 
[2,17,18]. 
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1.4. Regulatory Framework  
 
The new Pharmacovigilance legislation, in force since July 2012, has brought one of the 
most significant changes to the regulation of human medicines in the European Union 
(EU). There were significant implications not only for applicants and holders of EU 
marketing authorisations, but also for patients, healthcare professionals (HCPs) and 
regulators [2,17,18]. 
 
The development of the pharmacovigilance legislation was based on the observation 
the adverse drug reactions (ADRs), ‘noxious and unintended’ responses to a medicine, 
being linked to around 197,000 deaths per year in the EU [2,17,18]. 
 
For this reason, in 2005, the European Commission began to review the safety 
monitoring European system. This included the sponsorship of an independent study, as 
well as a thorough public consultation throughout 2006 and 2007.  
As a result of the these measures, in December 2010 a new Directive and Regulation 
was adopted by the European Parliament and Council of Ministers. This led to significant 
changes in the safety monitoring of medicines throughout the EU [2,17,18]: 
- Directive 2010/84/EU 
- Regulation (EU) No 1235/2010 
 
This new legislation amended the existing pharmacovigilance laws contained 
in Directive 2001/83/EC and Regulation (EC) No. 726/2004. It was also accompanied by 
the Implementing Regulation, a legally binding act published by the European 
Commission in June 2012 that provides details on the operational aspects for the new 
legislation: Commission Implementing Regulation No 520/2012 of 19 June 2012 
[2,17,18].  
 
Additionally, practical measures to reinforce the new legislation are available for 
consultation in the guideline on Good Pharmacovigilance Practices (GVP). This 
guideline is applicable for MAHs, EMA and medicines regulatory in EU Members States 
(for all medicinal products: NAPs and CAPs) [2,17,18]. 
 
The GVPs describe practical measures to facilitate the performance of the 
pharmacovigilance practices in the EU. This guideline is divided into chapters which fall 
into two categories: modules covering major pharmacovigilance processes, and product 
or population-specific considerations. GVPs Modules from I to XVI cover major 
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pharmacovigilance processes and are available on the EMA website [1]. In fact, the GVP 
modules replaced Volume 9A of The Rules Governing Medicinal Products in the 
European Union – Guidelines on Pharmacovigilance for Medicinal Products for Human 
Use [12].  
 
EU law therefore requires each MAH, national competent authority and EMA to operate 
a pharmacovigilance system. The overall EU pharmacovigilance system operates 
through cooperation between the EU Member States, EMA and the European 
Commission. In some Member States, regional centers are in place under the 
coordination of the national competent authority [2]. 
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1.5. Aims of the pharmacovigilance legislation 
 
The overall main purpose of the new pharmacovigilance legislation is to reduce the 
number of ADRs in the EU through [3,17]: 
- the collection of quality data of medicines and their safety; 
- rapid and robust assessment of issues related to the safety of medicines; 
- effective regulatory action required to deliver safe and effective use of medicines; 
- empowerment of patients through the increase in reporting and participation; 
- increased levels of transparency and better communication. 
 
The legislation made therefore an impact on marketing-authorisation holders and 
applicants. It aimed to make their roles and responsibilities clearer, minimize duplication 
of effort, release resources by rationalizing and simplifying reporting on safety issues, 
and establish a clear legal framework for post-authorisation monitoring [3,17]. 
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1.6. Pharmacovigilance Risk Assessment Committee  
 
The Pharmacovigilance Risk Assessment Committee (PRAC) is the European 
Medicines Agency's (EMA) committee that is responsible for assessing all aspects of the 
risk management of medicines for human use across the European Economic Area, from 
signal management to periodic safety update reports (PSURs) and risk management 
plans (RMPs). It is also involved in the design and evaluation of some post-authorisation 
safety studies (PASS) and coordinates the European PV agency inspection programme 
[19,20].  
 
The main responsibility of PRAC is to prepare recommendations on any questions 
relating to PhV activities of a medicine for human use, on signal management, and on 
risk-management systems, including monitoring of the effectiveness of such systems 
[19,20].   
 
Where necessary, the PRAC can impose a PASS to the Marketing Authorisation Holder 
of a medicinal product as a condition of the marketing authorisation or a specific 
obligation under exceptional circumstances. PASS may be also be required by the PRAC 
to investigate a safety concern in the product risk management plan or to evaluate the 
effectiveness of risk minimisation activities [19,20]. 
 
A particular focus in 2017 was signal management, with the introduction of enhanced 
Eudravigilance functionality on 22nd November 2017 and associated requirements for the 
industry to forward all validated signals to PRAC for evaluation [19]. 
 
A recently published document by EMA, on April 21, 2017, states that since its 
establishment in September 2012, PRAC has discussed and make the results public of 
its discussions on more than 600 signals [19]. 
 
The PRAC make available recommendations on issues on pharmacovigilance and risk 
management systems, including the monitoring of their effectiveness, to the [20]:  
- Committee for Medicinal Products for Human Use (CHMP) for centrally 
authorized medicines and referral procedures; 
- Coordination Group for Mutual Recognition and Decentralised procedures – 
Human (CMDh) on the use of a medicine in Member states; 
- the EMA secretariat, Management Board and European Commission, as 
applicable.  
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Important safety Issues via Referrals 
 
A referral is a procedure used to resolve issues such as concerns over the safety or 
benefit-risk balance of a medicine or a class of medicines [34]. 
 
In a referral, the European Medicines Agency is requested to conduct a scientific 
assessment of a specific medicine or class of medicines on behalf of the European Union 
(EU). The medicine, or the class of medicines, is ‘referred’ to the Agency so that it can 
make a recommendation for a harmonized position across the EU [34]. 
 
Relevant information from the literature, including pharmacoepidemiological studies and 
meta-analysis, from non-clinical studies, spontaneous reports and clinical trials, and any 
available academic research are fed into the assessment. Referrals offer opportunities 
for involving scientific advisory groups and for engaging patients and researchers, who 
can each contribute to the assessment from their specific angle. A referral can be 
triggered for products belonging to any therapeutic class, including both established and 
innovative medicines. Results of referral procedures contribute towards an optimised use 
of medicinal products. For instance, they have recently led to new recommendations to 
minimise the risk of teratogenicity in patients taking isotretinoin. Information on the 
commencement of the referral, the timetable, list of affected products and questions for 
the MAHs is promptly published on the EMA’s website [36], thus allowing real-time 
transparency. Relevant MAHs are notified and asked to contribute to the referral, 
including the provision of data and information for the PRAC’s assessment. The PRAC 
recommendation on the safety issue is then forwarded to the Committee for Medicinal 
Products for Human Use for opinion or, if no CAPs is involved, to the Coordination Group 
for Mutual Recognition and Decentralised Procedures—Human for its agreement. Once 
the evaluation is concluded, the PRAC assessment report outlining the outcome of the 
referral procedure is also published on the EMA website. Safety referrals are a very 
effective pharmacovigilance instrument to coordinate a thorough and timely review of the 
safety of products including those authorised via different procedures. Referrals result in 
a harmonised position across the EU, ratified by a decision that is immediately 
implementable and legally binding for all the MSs [22]. 
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1.7. Quality management system 
 
To fulfill the requirements of the legislation, MAHs, NCAs and the EMA have to establish 
and use adequate and effective quality systems. A quality system comprehends the 
settling of structures and processes (quality planning), the carrying out of tasks and 
responsibilities in accordance with quality requirements (quality adherence), the 
monitoring and evaluation of effectiveness of structures and processes (quality control 
and assurance) and the correction and improvement when necessary (quality 
improvements). The overall quality objectives of a pharmacovigilance system are to 
comply with the task and responsibilities set up in the legislation, prevent ADRs and 
promote the safe and effective use of medicinal products, thus contributing to public 
health [22,23]. 
 
For every authorized medicinal product, MAHs are required to maintain a description of 
their pharmacovigilance system in the pharmacovigilance system master file, which 
includes information relating to the persons (e.g. qualified person responsible for 
pharmacovigilance in the EU), as well as of the procedures put in place to ensure the 
safety of medicines. A copy of the pharmacovigilance system master file may be 
requested at any time and is usually requested during pharmacovigilance inspections. 
The EMA and the MSs need to cooperate and maximise their resources to continuously 
develop pharmacovigilance systems capable of achieving high standards of public health 
protection for all medicinal products, regardless of the routes of marketing authorisation. 
Additionally, to facilitate interaction between NCAs, the EMA, the EC and MAHs, 
competent authorities have to keep accessible descriptions of their organisational 
structures, assignment of tasks and responsibilities, and contact points [22,23]. 
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1.8. Pharmacovigilance System Master File 
 
1.8.1. Definition  
 
The Pharmacovigilance system master file (PSMF) definition is provided in Article 1(28e) 
of Directive 2001/83/EC as “a detailed description of the pharmacovigilance system used 
by the marketing authorisation holder with respect to one or more authorized medicinal 
products”. The minimum requirements for its content and maintenance are detailed in 
the Commission Implementing Regulation (EU) No 520/2012. 
 
The detailed requirements provided by the Commission Implementing Regulation are 
further supported by the guidance in GVP Module II of the Good Vigilance Practice(s) 
[21].  
 
In summary, the PSMF comprehends all aspects of pharmacovigilance activities, 
including information on the tasks that are subcontracted. The marketing authorization 
holder retains ultimate responsibility for compliance with the legal arrangements [21]. 
 
Additionally, the PSMF is used as a basis to the appropriate arrangement and conducting 
of the marketing authorization holder’s audits as well as a tool for EU Qualified Person 
for Pharmacovigilance (QPPV) to maintain supervision over the PhV System. The PSMF 
must be permanently available for inspection by the relevant competent authorities to 
verify its compliance with all aspects of the pharmacovigilance system [21]. 
 
1.8.2. Location  
 
The location of the PSMF should be either at the site in the EU where the major 
pharmacovigilance activities of the MAH are performed, or at the place in the EU where 
the qualified person responsible for pharmacovigilance operates. Its location or any 
changes are required to be entered and immediately updated both in the extended 
Eudravigilance Medicinal Product Dictionary (XEVMPD) and on the European medicines 
web portal [21].   
 
The PSMF possesses a unique code, the reference number, which is assigned by the 
Eudravigilance (EV) system, when the location information of PSMF with the format of 
Extended Eudravigilance Medicinal Product Report Message (XEVPRM) is entered [21]. 
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When submitting a Marketing Authorisation request, the applicant shall include the 
location of the PSMF electronically and its reference number in the application [21].   
 
The PSMF may be stored either in paper or in electronic form. It can be a digital 
document, existing either on different servers of the company or at suppliers of data 
services, but a clearly arranged printed copy must be directly available for inspection at 
the office address [21]. 
 
1.8.3. Contents of the Pharmacovigilance System Master File  
 
Except for aspects covered by the article 8 of Directive 2001/83/EC related to changes 
to the summary of the pharmacovigilance system, including, for instance, changes to the 
location of PSMF or the QPPV’s name and his or her contact details, other changes of 
the content of PSMF do not have to be notified to the Competent Authority and are not 
expected to require a variation request [21]. 
In former cases, those changes should be immediately notified to the Agency as well as 
being accompanied by an update of the Eudravigilance database, and where necessary, 
an update of the European medicines web-portal [21]. 
It should be included in the summary of the applicant’s pharmacovigilance system [21]: 
 Proof that the applicant has at his disposal a qualified person responsible for 
pharmacovigilance (QPPV);  
 The Member States in which the qualified person has their residence and carries 
out his/her tasks; 
 The contact details of the qualified person;  
 A statement signed by the applicant referring that the applicant has the 
necessary means to fulfil the tasks and responsibilities listed in Title IX; 
 Reference to the location where the pharmacovigilance system master file is 
kept. 
 The minimum requirement for contents of the PSMF and its maintenance are set 
out in the Commission Implementing Regulation (IR) (EU) No 520/2012 on the 
performance of pharmacovigilance activities for in Regulation (EC) No 726/2004 
and Directive 2001/83/EC. 
 The following elements should be included in the PSMF: 
 Information referring to the Qualified Person for Pharmacovigilance (QPPV): with 
the description of his responsibilities where he has enough authority over the 
pharmacovigilance system to promote, maintain and improve compliance with 
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predestined tasks and responsibilities; contact details; Curriculum Vitae; proof of 
his registration in Eudravigilance database; a description of an alternative to be 
followed in the absence of the QPPV; and a contact person for the 
pharmacovigilance where such person is introduced at the national level in 
accordance with the Article 104(4) of Directive 2001/83/EC, including contact 
details; 
 The organizational structure of the MAH, which shall include the sites where 
different pharmacovigilance activities take place (individual case safety report 
collection, evaluation, safety database case entry, periodic safety update report 
production, signal detection and analysis, risk management plan management, 
pre- and post-authorization study management and management of safety 
variations to the terms of a MA); 
 The description of the computerized systems and databases used to handle the 
safety information, including an assessment of their capabilities and their fit for 
this purpose;  
 Description of how data is handled, recorded and the processes used for each 
of the pharmacovigilance activities: risk-benefit monitoring, operation of the RMP 
and monitoring of the results of RMM. Collection, evaluation and reporting of 
individual case safety reports, preparation and submission of periodic safety 
update report, procedures for communicating the safety concerns with 
healthcare professionals as well as general public, and implementation of safety 
variations to the summary of product characteristics and package leaflet;  
 The content of the quality system, including the location of qualification records 
of the personnel, a summary of the training concept with reference to the training 
files, instructions and critical processes. It must include the presentation of the 
record management system with reference to the site where the documents used 
in PhV activities are, and the description of the how the performance of the PhV 
System is monitored; 
 Lastly, a description of the activities and/or services subcontracted by the MAH, 
when applicable. 
 
1.8.4. Contents of Annex of the Pharmacovigilance System Master File 
 
As for the Annexes of the PSMF it should include: 
1. Annex A: The Curriculum Vitae of the QPPV and associated documents, lists 
of the QPPV’s delegated activities and the persons, as well as to whom they 
are delegated;  
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2. Annex B: A list of contracts and agreements, including the subcontractors; 
 
3. Annex C: Lists of the safety data sources, including affiliates and third party 
contacts;  
 
4. Annex D: A list of computerized systems and databases;  
 
5. Annex E: Lists of written policies and procedures, for the specific quality system 
and processes to ensure:  
a. the continuous monitoring of pharmacovigilance data and risk 
minimization activities of the MAH;  
b. scientific evaluation of the risks of medicinal products by the MAH;  
 
6. Annex F: Lists of performance indicators used by the MAH and the results of 
performance assessment to continuously assure the good performance of 
pharmacovigilance activities;  
 
7. Annex G: scheduled and completed audits; 
 
8. Annex H: A list of all medicinal products covered by the PSMF and the name 
of Member State(s), in which the medicinal product is authorized (this list should 
be organized in accordance with the Active Substances and shall refer to the type 
of procedure for authorization and procedure number and presence of medicinal 
product on the market in the EU and other (non-EU) territories);  
 
9. Annex I: A logbook, which ensures that any changes in the contents of PSMF, 
made within the previous 5 years, will be recorded referring to the person 
responsible for the alteration and the reason for that change (where appropriate). 
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1.9.  Risk Management System 
 
1.9.1.  Definition  
 
A Risk Management System (RMS) can be defined as a set of Pharmacovigilance 
activities and interventions designed to identify, characterize, prevent or minimize risks 
relating to medicinal products including the assessment of the effectiveness of those 
activities and interventions [9]. 
 
 
Figure 1: Risk Management cycle 
 
 
 
A RMP is a detailed description of the RMS for a medicinal product and its requirement 
was firstly introduced in the EU legislation (the Regulation) in 2005.  
A RMP summarizes the safety profile of a medicinal product, registers the safety 
concerns such as the important identified risks, important potential risks as well as the 
missing information, and lists the further studies that will be carried out after the 
marketing authorization as well as any applicable Risk minimization measures [24]. 
For MAs granted after 21 July 2012, MAHs must operate a RMS for each medicinal 
product. Holders of MAs granted before this time are not required to operate a RMS for 
those medicinal products unless either the regulator or the MAH are concerned about 
risks affecting the benefit–risk profile of previously authorized medicinal product [24]. 
 
When a RMS for a medicinal product is created, it is mandatory that the MAH: 
IMPLEMENT
DATA 
COLLECTION
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- Ensures that the risks of their medicines are constantly being monitored in accordance 
to the legislation, as well as to report the results to the appropriate Competent Authority 
if applicable; 
- Takes all necessary measures to minimize the risks of their products and maximizes 
the benefits, including ensuring that the information is accurately produced by the 
company, and actively updating and communicating it when new information becomes 
available [24]. 
 
1.9.2.  Risk Management Plan (RMP) 
 
The Risk Management Plan is a detailed description of the risk management system, 
and may contain the Safety Specifications, the Pharmacovigilance Plan, and the Risk 
Minimization Plan. The RMP is a dynamic document that should be updated throughout 
the life cycle of the medicinal product [24]. 
 
Guidance on format of the RMP in the European Union may be found in the related EMA 
guidance [27], and the content of the document is compiled according to the Guideline 
on good Pharmacovigilance Practices (GVP) Module V [26]. 
 
The RMP is a detailed description of the risk management system, and should contain 
three main sections (it will be described, further ahead, in more detail):  
- Safety Specification  
- Pharmacovigilance Plan  
- Risk Minimisation Plan  
The purpose of the Safety Specifications is to explicitly consider the level of safety that 
has been demonstrated so far. It should identify what is already known about safety and 
what is not yet known. The Safety Specifications are a set of important identified risks, 
important potential risks as well as missing information. These are not meant to describe 
all the identified ADRs for the product but to identify the important risks of the product as 
well the missing information (e.g. special populations) which might have a significant 
impact on the B/R balance of the product and are passive and in need of further 
characterization [24,26]. 
 
The Pharmacovigilance Plan should indicate how this further characterization will be 
achieved in practice. It should contain the: 
- Expected levels of use of the product over time; 
- Strategies to address existing and potential safety signals; 
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- Strategies to monitor recognized serious ADRs in order to ensure that their incidence 
is low; 
- Strategies to address areas where safety knowledge is incomplete; 
- Proposed milestones at which a greater level of safety experience is expected to have 
demonstrated. 
 
Sometimes the Pharmacovigilance plan alone may not provide sufficient safeguards 
against known or serious potential hazards. In these cases, a Risk Minimization Plan is 
required. 
 
A risk minimization plan includes a set of Risk Minimization Measures (RMMs) which are 
a set of activities that need to be implemented in order to prevent or at least reduce the 
risk of harm from the event associated with a particular safety concern [29]. 
 
Following the review of the RMP, the summary for the public is shared with the company 
prior to publication and published at the time as part of the European Public Assessment 
Report (EPAR) (at time of Commission decision; this activity started in 2014 at the level 
of the EMA for CAPs). Important to note is that this is linked to the product information, 
European Public Assessment Report summary and list of medicines under additional 
monitoring. It shall not be forgotten that the RMP shall be continuously updated during 
the lifecycle of the medicinal products and updates should be submitted when major 
variations occur such as new indications, restrictions of indication, new or updated 
contraindications, new important risks or important changes to known risks, and any 
‘additional risk minimization measures’ are added or removed. This is within the concept 
of the continuous circle of collecting data, reporting and evaluating the B/R profile and 
confirming whether it remains favorable [24,26].  
 
1.9.3. Objectives of RMP 
 
The RMP must contain the following elements which:  
 Identify or characterize the safety profile of the medicinal product(s) including 
what is known and not known and, importantly, which risks need to be 
characterized or managed proactively (the “safe specification”); 
 
 Plan pharmacovigilance activities to characterize and quantify serious or clinically 
relevant risks of adverse reactions and to identify new adverse reactions (the 
“Pharmacovigilance Plan”);  
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 Plan and implement risk minimization measures, including the evaluation of the 
effectiveness of these activities (the “Risk Minimization Plan). 
 
1.9.4. Content of the RMP  
 
The RMP is divided into several sections, organized into modules to increase flexibility 
[26]: 
 Part I Product(s) Overview  
 Part II Safety Specification  
- Module SI: Epidemiology of the indication(s) and target population(s)  
- Module SII: Non-clinical part of the Safety Specification  
- Module SIII: Clinical trial exposure  
- Module SIV: Populations not studied in clinical trials  
- Module SV: Post-Authorization Experience  
- Module SVII: Identified and potential risks  
- Module SVI: Additional EU requirements for the Safety Specification  
- Module SVIII: Summary of the safety concerns  
 Part III Pharmacovigilance Plan- Routine Pharmacovigilance activities  
 Part IV Plans for post-authorization efficacy studies  
 Part V Risk minimization measures (including evaluation of the effectiveness of 
risk minimization measures)  
 Part VI Summary of the RMP  
 Part VII Annexes  
 
1.9.5. Updated and Timelines to the RMPs 
 
At the time of application for a marketing authorization companies submit a risk 
management plan (RMP), although in some circumstances certain parts can be omitted 
(for instance in generics) [26]. 
 
As new data is available, RMPs are continually modified and updated throughout the 
lifecycle of the medicine. Companies need to submit an updated RMP: 
- at the request of NCA or by the Agency; 
- every time the risk management system is changed, in particular because of new 
information that is raised which may lead to a significant change of the benefit/risk 
balance, or as a result of an important pharmacovigilance or risk-minimisation milestone 
being met. In case an RMP is previously submitted by the applicant, the following 
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submissions must be in the form of an update, unless requested otherwise. Each 
submission of the RMP will have an indicative version number and date [26].  
 
1.9.6. Risk Minimization Measures (RMMs) 
 
The objective of the Risk minimisation measures is to prevent or reduce the appearance 
of adverse reactions, or to reduce their severity and impact on life quality of the patient. 
It is vital that these RMMs be planned and implemented, and its effectiveness be 
evaluated [29]. 
 
Routine measures are applied to every medicinal product. In addition, further risk 
minimisation activities should only be addressed when they are deemed to be essential 
for the safe and effective use of the drug [29]. 
 
Therefore, RMMs typically are classified in two types [29]:  
 Routine risk minimization: comprehending product information updates, such as 
changes of the legal status, packing size, SmPC, Package leaflet and Labelling; 
 or Additional Risk Minimization: consisting in the control or restriction of the 
product’s access or use, distribution of educational materials or providing training 
programs (e.g. prescription checklists, pregnancy prevention programs, patient 
alert cards, others), as well as the distribution of Direct Healthcare Professionals 
Communications (DHPC).  
 
The Directive 2001/83/EC indicates that MAH should “Monitor the outcome of risk 
minimisation measures which are described in the RMP or which are laid down as 
conditions of the MA”. The Directive and the Regulation (EC) No 726/2004 also include 
provisions for the agency and NCA to monitor the outcome of the RMM.  
 
Beyond studies and measures described in the risk management plan, the PRAC assess 
both protocol and results of imposed post-authorisation safety studies aiming the 
evaluation of the effectiveness of risk minimization measures [29]. 
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1.10. Periodic safety updated report (PSUR)  
 
The PSUR presents a comprehensive and critical analysis of the B/R balance of the 
medicine, submitted by the MAHs at defined time points throughout the post-
authorisation phase. It considers new and emerging data in the context of cumulative 
information about risks and benefits [30].  
 
The objective of the Periodic Safety Update Reports (PSURs) is to facilitate the regular 
and systematic review of the global safety data available to MAH. The goal of such review 
of the data in the PSUR may lead to new safety issues being identified [30].  
 
The development of PSURs starts when a drug is first approved for marketing anywhere 
in the world and, initially, reports are produced on a six-monthly basis. The period 
covered becomes longer once the drug is established in the market [30]. 
 
PSUR reporting should be linked to the risk management plans (RMPs) of a medicinal 
product. The “modular approach” of the PSUR described in GVP Module VII intends not 
only to minimise the duplication but also to improve efficiency during the preparation and 
review of PSURs along with other regulatory documents such as the development safety 
update report (DSUR) or the safety specification in the RMP [30]. 
 
1.10.1. Format and content of PSUR 
 
The new format is described in GVP Module VII. The GVP Module VII provides guidance 
on the preparation, submission and assessment of PSURs. The format and content of 
PSURs in the EU are based on those for the Periodic Benefit Risk Evaluation Report 
(PBRER) described in the ICH-E2C. 
 
The PSUR should be based on all available data and shall focus on new information 
which has been obtained since the data lock point of the last PSUR. It should be taken 
into account cumulative information when performing the overall safety evaluation and 
integrated benefit-risk assessment [30]. 
 
The PSUR should present summaries of data that are relevant to the benefits and risks 
of the product, including results of all studies with a consideration of their potential impact 
on the marketing authorisation [30]. 
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1.10.2. Timelines and submission of PSUR 
 
Marketing authorisation holders for products authorised before 2nd July 2012, for centrally 
authorised products, and 21st July 2012, for nationally authorised products, and for which 
the frequency and dates of submission of PSURs are (a) not a condition to the marketing 
authorisation or (b) determined otherwise in the list of Union reference dates (EURD List) 
shall submit PSURs according to the submission schedule below: 
- At 6 months intervals once the product is authorised, even if it is not marketed;  
- Once a product is marketed, a 6 monthly PSUR submission should be continued 
following initial placing on the market in the EU for 2 years, and afterwards once a year 
for the following 2 years, and thereafter at 3-yearly intervals.  
 
1.10.3. List of European Union Reference dates  
 
The list of Union reference dates, and frequency of submission of periodic safety update 
reports, is a list of active substances and its combinations for which Periodic Safety 
Update Reports should be submitted in accordance with the EU reference dates and 
frequencies determined by the Committee for Medicinal Products for Human Use 
(CHMP) and the Coordination Group for Mutual Recognition and Decentralized 
Procedures - Human (CMDh), following consultation with the Pharmacovigilance and 
Risk Assessment Committee (PRAC) [32]. 
 
The EU reference dates list has been compiled to facilitate the harmonization of Data 
Lock Points (DLPs) and frequency of submission of PSURs for medicinal products 
containing the same active substance, or a combination of these, subject to different 
marketing authorisations authorised in more than one Member State [32,32].  
 
1.10.4. PSUR vs RMP 
 
While PSUR is retrospective, with an integrated approach, and the assessment of the 
risk-benefit is performed during the post- authorisation period, the RMP is prospective 
and its risk-benefit management and planning are done either during the pre- and post-
authorisation period. Thus, the two files are complementary [25,30].  
 
During the preparation of a PSUR, the marketing authorisation holder should consider if 
any identified or potential risk discussed in the PSUR is important and requires an update 
of the RMP [25,30]. 
   Page 24 of 175 
If so, an updated and revised RMP including the new important safety concern should 
be submitted with the PSUR and assessed in parallel, following the timetable for the 
assessment of PSUR as described above [30]. 
 
If the important safety concern is identified by the national competent authority during 
the assessment of a PSUR and no updated RMP or no RMP had been submitted, the 
agency will typically recommend submitting an updated or a new RMP within a defined 
timeline [30]. 
   Page 25 of 175 
2. Methods 
 
The main purpose of this work is to demonstrate the complexity of the pharmacovigilance 
system and its regulatory requirements by presenting practical examples in the real 
world. The methods used for the performance of this practical work was the public 
revision of the Current European Legislation, Guidelines and recommendations found in 
the EMA Website and European Commission. 
 
Main ideas: 
 Pharmacovigilance is a dynamic and complex area. Understand how the 
processes work in practice is the focus of this work. 
 Creation of a fictional company and attempt to implement the main PhV 
requirements, namely the PSMF and the RMP. 
 The medicinal product chosen for this discussion was isotretinoin mainly due to: 
- The well know adverse reactions (mainly teratogenicity). 
- Ongoing safety referral procedure triggered by the negative outcome of 
the evaluation of the effectiveness of the existing RMM in place (e.g. 
PPP). 
- Understand all measures which need to be applied by the MAH 
following the PRAC recommendations in order to increase the safety  of 
isotretinoin and ultimately optimise the use of the product.
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3. Results 
 
In the following pages it will be demonstrated practical examples of a Pharmacovigilance 
System Master File presentation, in the fictional company Stala Pharma, as well as the 
importance of the Risk Management Plan through a practical example of the medicinal 
product Isotretinoin Generic with detailed proposals of implementation of risk 
minimization measures. 
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RMR - Reaction Monitoring Report 
SmPAR - Summary Pharmacovigilance Assessment Report 
SmPC – Summary of Product Characteristics 
SOP - Standard Operating Procedure 
XEVMPD - eXtended EudraVigilance Medicinal Product Dictionary 
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XEVMPD Code: MFL0030 
 
Marketing Authorisation Holder Contact Details: 
Name: Stala Pharma - Pharmaceutical Products, S.A. (Stala Pharma P) 
Address: Rua Alexandre Pinto, nº105, 3º esq, 2800-039 
Lisbon – Portugal 
 
Name: Stala Pharma - Generics, S.A. (Stala Pharma G) 
Address: Rua Alexandre Pinto, nº105, 3º esq, 2800-039 
Lisbon – Portugal 
 
The Stala Pharma - Pharmaceutical Products, S.A. shares the same pharmacovigilance 
system master file with Stala Pharma - Generics, S.A. 
 
Qualified Person for Pharmacovigilance Name address and contact details  
Name: Patrícia de Lurdes Douteiro Rodrigues   
Address: Rua Alexandre Pinto, nº105, 3º esq, 2800-039 Lisbon, Portugal 
Telephone: +351211122333 
Mobile (24-hour): +351911122333  
E-mail address: PhV@stalapharma.pt 
 
 
Pharmacovigilance System 
Master File 
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II.B.4.1. Qualified person responsible for pharmacovigilance (QPPV) 
 
As part of the pharmacovigilance system, the MAH shall have permanently and 
continuously at its disposal an appropriately qualified person responsible for 
pharmacovigilance in the EU (QPPV) [DIR Art 104(3)((1)a)]. Each pharmacovigilance 
system can have only one QPPV.  
The MAH shall ensure that the QPPV has sufficient authority to influence the 
performance of their quality system as well as their pharmacovigilance activities. The 
MAH should therefore ensure that the QPPV has access to the PSMF as well as authority 
over it and is notified of any changes to it. The authority over the pharmacovigilance 
system and the PSMF should allow the QPPV to implement changes to the system and 
to provide input into RMPs.  
Overall, the MAH should ensure that structures and processes are in place, so that the 
QPPV can fulfil their responsibilities and therefore, the MAH should ensure that 
mechanisms are in place so that the QPPV receives all relevant information and that the 
QPPV can access all information the QPPV considers relevant, in particular on:  
• emerging safety concerns and any other information relating to the benefit-risk 
evaluation of the medicinal products covered by the pharmacovigilance system;  
• ongoing or completed clinical trials and other studies the marketing authorisation 
holder is aware of and which may be relevant to the safety of the medicinal products;  
• information from sources other than from the specific marketing authorisation holder, 
e.g. from those with whom the marketing authorisation holder has contractual 
arrangements;  
•the procedures relevant to pharmacovigilance which the marketing authorisation 
holder has in place at every level in order to ensure consistency and compliance across 
the organisation.  
Thus the QPPV should be have adequate theoretical and practical knowledge for the 
performance of pharmacovigilance activities [IR Art 10(1)]. The QPPV should have skills 
for the management of pharmacovigilance systems as well as expertise or access to 
expertise in relevant areas such as medicine, pharmaceutical sciences as well as 
epidemiology and biostatistics. The MAH should provide the QPPV with training in 
relation to its pharmacovigilance system, which is appropriate for the role prior to the 
QPPV taking up the position and which is appropriately documented. Consideration 
should be given to additional training, as needed, of the QPPV in the medicinal products 
covered by the pharmacovigilance system. 
The designated EEA Qualified Person for Pharmacovigilance of the Stala Pharma is 
Patrícia Rodrigues and the Deputy-QPPV is Joana Silva. 
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The authority of the EEA Qualified Person for Pharmacovigilance over the 
pharmacovigilance system is ensured via the Pharmacovigilance Group Policy, as well as 
by a SOP and the respective job description in annex A.  
 
The responsibilities of the EEA Qualified Person for Pharmacovigilance can be 
summarized as follows: 
- Have access to and ensure that the Pharmacovigilance System Master File 
(PSMF) is in place, is accurate and up to date; 
- Maintain an overview of the safety profiles and of any emerging safety issues of 
the company products. Act as the local pharmacovigilance contact point for the 
regulatory authorities on a 24-hour basis and also as a contact point for 
pharmacovigilance audits or inspections;  
- Maintain awareness of the any conditions or obligations adopted as part of the 
Marketing Authorization as well as any risk minimization measures;  
- Have authority and sign off on Risk Management Plans (RMPs).  The QPPV usually 
signs off on PSURs and DSURs also; 
- Being involved in the revision and sign-off of protocols of PASS; 
- Having consciousness of PASS requested by a competent authority including 
results of such study; 
- Ensuring that Quality Control (QC) and Quality Assurance (QA) mechanisms are 
in place to keep the MAH in compliance; 
- SOPs and Working Documents covering PV are in place, up-to-date, trained on 
and actually followed; 
- A quality management system (QMS) is in place which includes audits, 
inspections, Corrective Action, Preventive Action plans (CAPAs) as needed and 
that they are actually put in place and completed; 
- Ensuring a full and prompt response to any request by the competent authority 
or by the agency for prevision of additional information; 
- Ensuring that PV training is done in the drug safety/PV department as well as 
anywhere (everywhere) else in the company (or vendors, third parties etc.) 
where safety matters may arise; 
- Ensure that written agreements with other companies (including business 
partners, vendors, and other third parties) are in place regarding safety and 
oversee their work; 
- Ensure that signal detection and trending mechanisms are in place; 
- Ensure that all suspected adverse drug reactions ADRs received by the MAH are 
collected and accessible at one or more points in the EU; 
- Ensure that ICSRs, PSURs and Post-Authorization Safety Studies (PASS) cases and 
any other safety commitments are reported appropriately to the competent 
authorities (CAs) and the Agency; 
- Ensure the continued evaluation of the benefit/risk analyses of all products; 
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- Ensure the conduct of pharmacovigilance and submission of all 
pharmacovigilance-related documents in accordance with the legal 
requirements and GVP; 
- Provide input into the preparation of regulatory actions in response to emerging 
safety concerns (e.g. variations, urgent safety restrictions, and communication 
to patients and healthcare professionals). 
 
 
1. Summary of the CV and key information on the role of QPPV  
The function of the QPPV at Stala Pharma is ensured by Dr. Patrícia Rodrigues, a 
pharmacist by background, who possesses the adequate pharmacovigilance training, 
knowledge and experience to fulfil this function. 
The QPPV is registered in EudraVigilance (proof of registration is presented in Annex A) 
and has followed the relevant training courses on electronic reporting of ICSRs in the EU 
and on the Extended EudraVigilance medicinal product dictionary.  
The QPPV is employed at Stala Pharma services and provides services to Stala Pharma 
Generics S.A. and Stala Pharma Products S.A. 
2. Contact Details 
Table 4 - EEA QPPV 
QPPV: Patrícia de Lurdes Douteiro Rodrigues 
Telephone: +351211122333 
Telephone (24h): +351911122333 
Fax: +351211122333 
Address: Rua Alexandre Pinto, nº105, 3º esq, 2800-039 Lisbon, Portugal 
Email: PhV@stalapharma.pt 
Country: Portugal 
 
3. Information relating to the contact person where such a person has been 
nominated at national level  
Patrícia Rodrigues has also been nominated at national level, in Portugal, as a contact 
person for pharmacovigilance in accordance with article 104 (4) of Directive 
2001/83/EC. 
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II.B.4.2. Organisational structure  
 
1. Description of Stala Pharma Group 
 
The Stala Group is composed by the following companies: 
1. Stala Pharma - Pharmaceutical Products, S.A. 
2. Stala Pharma - Generics, S.A. 
3. Stala Pharma – Services, Lda.    
 
 
 
       The Stala Pharma - Pharmaceutical Products, S.A. and the Stala Pharma - Generics, 
S.A. are Marketing Authorisation Holders and share the same Pharmacovigilance Master 
File. 
 
The Organisational Chart of Stala Pharma is presented below: 
 
 
 
The Stala Pharma – Services is an internal service provider operating under the same 
person’s authority, the Managing Director. 
 
 
 2. Qualified Person for Pharmacovigilance and Deputy QPPV 
 
The QPPV and Deputy QPPV are both employees of Stala Pharma – services. They fulfil 
the QPPV and Deputy Position for the companies within the group: Stala Pharma - 
Pharmaceutical Products, S.A. and the Stala Pharma - Generics, S.A. 
General Manager
Regulatory Affairs 
Department
Pharmacovigilance 
Department
Quality assurance
Accounting Office Human Resources
Business 
Development
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The Pharmacovigilance Department is constituted by the QPPV, Deputy QPPV, 
Pharmacovigilance Officer and Pharmacovigilance Junior Officer. 
 
Organogram of Pharmacovigilance Department 
 
 
 3. Conduct of the Pharmacovigilance Activities  
 
The Pharmacovigilance activities and processes are conducted at only one location, 
where the Pharmacovigilance System Master File (PSMF) as well as the EU QPPV and 
Deputy are located. 
Stala Pharma Services centralises the fulfilment of the Pharmacovigilance activities for 
the companies of the group, as can be found in the following diagram: 
 
 
 
 
 
 
 
 
 
General Manager
Dr. Paulo Magalhães
Pharmacovigilance 
officer
João Sousa
Pharmacovigilance 
Junior officer
Bernardo de Araújo
Pharmacovigilance 
Department
Medical consultant
Dr. Eduardo Souto
QPPV
Patrícia Rodrigues Deputy-QPPV
Joana Silva
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Nevertheless, there are some exceptions. The collection of ICSRs is performed by each 
of companies of the group. The delegated tasks listed in annex A as well as the auditing 
of the Pharmacovigilance master file that is performed by an independent contractors 
or by internal auditor who is independent from the Pharmacovigilance Department. 
 
 3.1. Collection of ICSRs 
 
The collection of ICSRs is performed by each company of the group Stala Pharma 
including Stala Pharma Services as well as the partners listed in Annex A. 
   
 3.2. All other Pharmacovigilance activities  
 
Except for the delegated tasks (as listed in annex A), Stala Pharma Services, in the person 
of both the QPPV and Deputy-QPPV, undertakes all the Pharmacovigilance activities for 
the group namely:  
 Case processing and evaluation;  
 Data entry in the safety database;  
 Case submission to the regulatory authorities;  
 Periodic safety update report management and preparation;  
 Signal detection and analysis;  
 Risk management plans management and preparation;  
 Management of Safety Data Exchange Agreements;  
 Pre and post-authorisation study management; 
 Management of Pharmacovigilance audits and inspections; 
 Etc… 
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II.B.4.3 The sources of safety data 
 
1. Sources of safety information 
The safety information at Stala Pharma can provided from:  
- Spontaneous Reporting Systems (by health professionals, manufacturers, sales 
representatives or directly by patients); 
- National PV Centre / Competent Authority; 
- Published scientific literature and Drug Bulletins;  
- Safety database; 
- Media; 
- Study results; 
- Foreign Regulatory Agencies; 
- Technical product complaints. 
 
2. Overview of routes for collection of safety information 
Safety information can be collected and reach the Pharmacovigilance Department at 
Stala Pharma by the following routes: 
- Any employee at Stala Pharma Group; 
- Consumers or patients (reporting by phone or email); 
- Internet; 
- Affiliate;  
- Partner/Distributor. 
 
A comprehensive list with the respective contacts can be found in Annex C. 
 
3. Sources of individual case safety reports 
The collection of safety information is done by all of the companies which take part in 
Stala Pharma Group (as described in section 2, Organizational Structure) as well as by 
the partners/distributors listed in Annex C. 
In general, all employees are sources of potential safety information and are instructed 
to forward that information to the Pharmacovigilance department within 24 hours.  
 
The pharmacovigilance mailbox address (phv@stalapharma.pt) as well as the telephone 
and mobile numbers of the QPPV and Deputy are provided to all upon training and are 
available on the company’s intranet. 
 
3.1. Unsolicited Reports 
 3.1.1 Spontaneous Reports 
- Unsolicited communication of ADRs; 
- By health care professionals or consumers; 
- In a patient who was given one or more medicinal products; 
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- do not derive from a study or any organized data collection scheme; 
- is “voluntary” reporting; 
- will not provide rates and incidences of ADRs. 
 
 3.1.2 Literature  
The pharmacovigilance Department is responsible for regularly to screen the worldwide 
scientific literature by accessing widely used systematic literature reviews or reference 
databases. The frequency of the literature searches is every week. 
 
 3.1.3. Internet 
Stala Pharma has a website where any person can consult the contacts and information 
regarding their products placed on the market. There is also the possibility of registering 
any suspicion of ADR. The pharmacovigilance Department should regularly screen this 
website for checking any potential ADR case reports. 
 
 3.1.4. Other Sources 
If Pharmacovigilance Department at Stala Pharm Group becomes aware of a case report 
from non-medical sources, e.g. the lay press or other media, it should be handled as a 
spontaneous report. 
 
3.2. Solicited Sources  
Solicited reports are those derived from organized data collection systems, which 
include clinical trials, registries, post-approval named patient use programs, other 
patient support and disease management programs, surveys of patients or healthcare 
providers, or information gathering on efficacy or patient compliance. In this moment 
there is not a study. 
 
3.3 Contractual Agreements 
Stala Pharm Group takes place through contractual agreements between different 
distributors/partners, which market the same product in different countries/regions.   
The Safety Data Exchange Agreements (SDEA) has been established between the 
different distributors. The timelines and processes for exchange will vary per partner but 
the collection and adequate processing of information is safeguarded. 
 
3.4 Regulatory Authority Sources 
Cases with regulatory origin are received directly by the Pharmacovigilance department 
mailbox.  
 
 
4. Processing of safety information 
Processing and reporting of safety information is always done by the QPPV and/or 
Deputy QPPV, unless otherwise agreement upon via a SDEA. 
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B.II.4.4. Computerized Systems & Databases 
 
1. Computerized Systems and their purpose 
The department of pharmacovigilance at Stala Pharma has a significant number of 
computerized systems to support the performance of its activities. Further information 
with regards to the systems in place can be found in annex D. 
 
1.1 Processing of safety information 
The database used to manage the ADRs was built on an excel spreadsheet and is 
inserted in the documental system Spotyver Plus. The access to this excel 
spreadsheet is blocked by a password and is only accessible by the 
pharmacovigilance department.  
 
1.2 Processing of other safety related information 
RegistMed is a system used to register incoming contacts in relation to medical 
information requests or enquiries, pharmacovigilance information or reports, 
product quality or technical complaints.  
 
1.3 Aggregate Reporting 
The structure of the PSUR is developed by using the eCTD Manager and their 
submission is made by the eSubmission Webclient (the tool made available by 
the EMA).  
 
Pharmacovigilance cases are submitted to the Agency through the 
EudraVigilance system, which is a thematic network allowing the exchange of 
pharmacovigilance data capable of producing XLM files and receiving 
confirmation messages. 
 
All additional documents are submitted to the competent 
authority/partners/distributors through the Eudralink, in order to ensure the 
confidentiality of the transmission. 
 
1.4 Document Management 
Spotyver Plus is the system used to manage and control documents within Stala 
Pharma Group. The life cycle of the documents is controlled via Spotyver Plus 
allowing a transparent generation, revision, approval, update, access, storage 
and discontinuation of documents within the Stala Pharma Group. 
 
All documents which are part of the PSMF are also stored and controlled within 
Spotyver plus. 
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1.4 Product information 
The submission and update of product information into the XEVMPD is done by 
the EV Webtrader (system made available by the EMA). 
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B.II.4.5. Pharmacovigilance Process 
 
A Quality Management System, with relevant procedures and processes, is in place in 
order to ensure the following: 
 
- The continuous monitoring of pharmacovigilance data, the examination of 
options for risk minimisation and prevention and appropriate measures are 
taken by Stala Pharma; 
- The scientific evaluation by Stala Pharma of all information on the risks of their 
medicinal products; 
- The submission of accurate and verifiable data on serious and non-serious 
adverse reactions to the Eudravigilance database; 
- The quality, integrity and completeness of the information submitted on the risks 
of medicinal products, including processes to avoid duplicate submissions and to 
validate signals; 
- Recording and traceability of the information; 
- Effective communication by Stala Pharma with national competent authorities 
and the agency, including communication on new risks or changed risks, the 
PSMF, risk management systems, risk minimisation measures, periodic safety 
update reports, corrective and preventive actions, and post-authorisation 
studies; 
- The update of product information by Stala Pharma in the light of scientific 
knowledge, including the assessments and recommendations made public via 
the European medicines web-portal, and on the basis of a continuous monitoring 
by Stala Pharma of information published on the European medicines web-
portal; 
- Appropriate communication by Stala Pharma of relevant safety information to 
healthcare professionals and patients. 
 
 
Each pharmacovigilance procedural document is described in the annex E. 
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B.II.4.6 Pharmacovigilance System performance 
 
1. The evaluation system used to assess the correct reporting of ICSRs 
The assessment of reporting requirements of ICSR is conducted within the 
Pharmacovigilance department. 
 
Compliance figures with reporting timelines are provided in Annex F. 
 
2. The metrics used to monitor the quality of submissions and performance of 
pharmacovigilance 
Compliance figures with reporting timelines are provided in Annex F. 
 
3. How PSUR submission to authorities is monitored 
The management of the PSUR schedule is the responsibility of the 
Pharmacovigilance department. 
 
The PSUR schedules (Excel based), one for each company of Stala Pharma, are 
prepared by one member of the Pharmacovigilance department. The schedules 
are updated according to the current legislation and are reviewed on a monthly 
basis. 
 
Compliance figures with reporting timelines are provided in Annex F. 
 
4. How variation submissions are monitored 
Compliance figures with reporting timelines are provided in Annex F. 
 
5. How Risk Management Plans Commitments, if any, are monitored 
 
There is a database used to manage RMP and the respective commitments. This 
database is verified at least on a yearly basis and the fulfilment of the described 
commitments is checked against what has been implemented. 
 
6. Other metrics used to evaluate the performance of the system. 
Compliance figures with reporting timelines are provided in Annex F. 
 
In accordance with Article 9 of commission implementing Regulation No. 520/2012 
Stala Pharma uses performance indicators to evaluate the performance of the 
system. In Stala Pharma’s PSMF a list of performance is present in annex F. The list 
is composed by the following indicators: 
- ADR/AE input management 
- Management of valid ADR 
- Literature Research 
- PSUR 
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- Risk Management Plan (RMP) 
- Safety variations 
- Security measures 
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B.II.4.7 Quality system 
 
“The Quality System (QS) is part of the PV system and consists of its own structures and 
processes. It shall cover organisational structure, responsibilities, procedures, processes 
and resources of the pharmacovigilance system as well as appropriate resource 
management, compliance management and record management (IR Art 8(2))…”   
 
1. Document and Record control 
Pharmacovigilance documents and records are kept in two formats: electronically and 
in paper.  
 
For pharmacovigilance processes, a database is used as the main document 
management system for electronic documents. It allows document search, document 
archive, requests for changes to documents in effect and the full audit trail of the 
document life cycle namely author, reviewers, approvers, document owner, changes 
made or requested to the documents, respective dates, etc...  
 
The documents Summary of the Applicant’s Pharmacovigilance System are archived 
electronically and in paper. The electronic format is maintained and controlled with 
Spotyver Plus and it was approved by the general director.  
 
All documents which are part of the PSMF are controlled documents with Spotyver Plus. 
The back-up of all documents available electronically is ensured via the back-up of the 
the servers at Stala Pharma Group. 
The hard copy of the pharmacovigilance related documents are archived in the 
aforementioned locked cabinets with restricted access. 
Recording all the information of PhV, handled and stored in such a way they can be 
reported, interpreted and verified thoroughly. 
Pharmacovigilance data and documents relating to individual medicines authorized 
preserved as required. 
Records management system for all documents used for pharmacovigilance activities 
are in place in order to:  
 Easily find these documents; 
 Track how and when were examined/made decisions on safety issues; 
 Tracking and follow-up of adverse reaction reports; 
 Keeping the elements of the PSMF according to law requirements. 
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2. Procedural documents 
A complete overview of procedural documents can be found in annex E – List of 
Procedural Documents. 
 
With respect to procedural documents, the Quality Management System of 
Pharmacovigilance is integrated in the Stala Pharma Quality System.  
 
The management of pharmacovigilance procedural documents is done Spotyver plus.  
 
There are currently four of pharmacovigilance procedural documents: 
 
1. SOPs: standard operating procedures describing in detail the who, what, how and 
when of the pharmacovigilance processes are performed;  
 
2. Summary of the Applicant´s Pharmacovigilance System: documents describing in 
summary the pharmacovigilance system of all Marketing Authorisation Holders of 
Stala Pharma.  
 
3. Pharmacovigilance system master file 
Documents regarding pharmacovigilance system master file and the respective 
annexes. 
 
4. Templates 
Models to be used in pharmacovigilance activities. 
 
All these documents are version controlled, have a reference number, an effective date, 
document owner, document approver and are entered in the database. The revision of 
existing procedures or triggering of the process for the implementation of new ones, is 
mainly of the responsibility of the Pharmacovigilance Department. Nevertheless, there 
are some situation where the responsibility is from another department listed in annex 
E.  
 
3. Training 
Organization chart and clear definition of roles and responsibilities (function in charge 
of PhV system implementation and oversight, execution, audit activities) is present in 
section 2 – Organisational Structure. 
 
At Stala Pharma, clearly defined roles, job descriptions and training documented are 
available for all individuals. 
 
An appropriate SOP describes in full detail the principles and processes for training of all 
staff members in pharmacovigilance matters.  
 
The initial training of any new employee of Stala Pharma must include introductory 
training in pharmacovigilance. 
Defined procedures to be followed in case of emergency (back up) must be in 
implemented at the beginning.  
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The archive of training documentation is maintained in a specific area under the 
responsibility of Human Resources. 
 
All pharmacovigilance employees must have Initial, documented and continuing 
training. 
 
Pharmacovigilance training can be provided at the office in Lisbon or on another 
location, depending on the number of attendees and goal of the training. 
 
 
4. Auditing  
The process for audit planning, budgeting, fulfilment, correction and prevention of non-
compliances, and follow-up auditing as well as the different types of audits that can be 
conducted and the risk based approach is described in appropriate SOP. 
Periodic audits based on risk and process analysis, with a defined audit PLAN allow: to 
ensure compliance with quality system requirements described; to determine the 
effectiveness and outsourced activities covered by audit plan. 
Annex G provides the strategic and the tactical audit programme, the overview of audits 
completed and the notes on previous significants’ findings (graded critical and major) 
that are currently unresolved or not yet independently verified. 
 
5. CAPA management 
Defined SOPs to track, manage and periodically review corrective and preventative 
actions, to be reported to senior management in management review. 
Deviation form is also used to determine the corrective action to be implemented as 
well as the staff responsible for that implementation. 
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Annex A 
1. Curriculum Vitae of QPPV Person 
 
PATRÍCIA RODRIGUES 
 
AVENIDA DA LIBERDADE, 58 – 2ºDIR; 2850-963, LISBON - PORTUGAL 
+ 351 91 22 33 444  ▪  douteiropatricia@gmail.com  
 
Date of birth: 02/01/1987  
Nationality: Portuguese  
Professional License Number: 18343   
Pharmaceutical Order Number – Portuguese Pharmaceutical Society: C-03359 
QPPV code (Eudravigilance): 58963 – Stala Pharma – Produtos farmacêuticos, S.A. 
   
WORK EXPERIENCE 
Qualified Person for Pharmacovigilance (QPPV)  
Stala Pharma - Pharmaceutical Products, S.A. ▪ October 2016 – present ▪ Lisbon, Portugal 
Pharmacovigilance Officer 
Phagesson - Pharmaceutical Services and Consulting ▪ January 2015 – September 2016 ▪ Lisbon, 
Portugal 
Global Project Manager, Pharmacovigilance 
UBP - An Express Scripts Company▪ October 2013 – December 2014 ▪ Genève, Switzerland  
Regulatory affairs officer   
Grupo Tecnipharma ▪ September 2010 - September 2013- Lisbon, Portugal 
 
ADDITIONAL INFORMATION – TRAINING 
 
Training course: (15 hours) Nov 15 - Pharmacovigilance Intensive Couse  
Training Course workshop (8 hours) Nov 15 – Quality Management at Pharmacovigilance  
Training Course (8 hours) Jun 15 MSSO – Coding with MEdDRA 
Training Course (8 hours) Jun 15 MSSO – MedDRA safety Data Analysis and SMQs 
Training Course (1 hours) Jun 15 EXTEDO – get ready for the 2014 XEVMPD Requirements 
Training Course: webinar Jun 15 EXTEDO – adverse event reporting: requirement of a contact 
person for pharmacovigilance and how to effectively manage your cases 
Training Course: webinar September 2014 - EMA: training sessions on e-submission Gateway 
and web client for PSUR single-assessment submissions 
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Training Course: (2 hours) Aug 15 MSSO- Introduction to MEDdra Dictionary  
Training Course: (3 days) July 14- Eudravigilance – Electronic Reporting of ICSRs in the EU 
attendance and approval 
Training Course: (2 days) Nov 14 - DIA- Extended Eudravigilance Medical Product Dictionary 
Attendance and Approval 
EDUCATION AND TRAINING University of Lisbon, Faculty of pharmacy 
2014 ▪  Master's degree, Regulation and Evaluation of Medicines and Health Products 
University of Coimbra, Faculty of pharmacy  
2005-2010 ▪  Master, Pharmaceutical Sciences 
PERSONAL SKILLS 
Mother tongue(s): Portuguese 
  
Other Language(s): 
 Understanding Speaking  Writing 
 Listening Reading Spoken 
interaction 
Spoken 
production 
 
English B2 B2 B2 B2 B2 
Spanish  B2 B2 B2 B2 B1 
France  B2 B2 B2 B2 B2 
Levels: A1/2: basic user – B1/2: independent user – C1/2 Proficient user 
Common European Framework of Reference for Languages  
 
Computer skills: good informatics knowledge as user 
Driving license: Type B 
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2. Curriculum Vitae of Deputy-QPPV Person 
 
EXPERIENCE 
 
Qualified person for Pharmacovigilance Deputy (QPPV Deputy) at STALA PHARMA 
 ▪ 10/2016 – Present ▪ Lisbon 
 
Pharmaceutical Affairs Officer at Sandiz Farmacêutica, Lda 
▪ 02/2015 – 09/2016 ▪ Lisbon 
 
Pharmacovigilance trainee at Medincinfa 
▪ 07/2014 – 01/2015 ▪ Lisbon 
 
EDUCATION AND TRAINING  
 
University of Lisbon, Faculty of Medicine 
2015 ▪ Intensive course of Pharmacovigilance  
 
University of Lisbon, Faculty of pharmacy 
2014 ▪ Master, Pharmaceutical Sciences 
 
EDUCATION AND TRAINING 
  
University of Lisbon, Faculty of Medicine 
2015 ▪ Intensive course of Pharmacovigilance  
  
University of Lisbon, Faculty of pharmacy 
2014 ▪ Master, Pharmaceutical Sciences 
 
 Understanding Speaking Writing 
 Listening Reading Spoken 
interaction 
Spoken 
production 
 
English B2 B2 B2 B2 B2 
Levels: A1/2: basic user – B1/2: independent user – C1/2 Proficient user 
Common European Framework of Reference for Languages  
 
Computer skills: good informatics knowledge as user 
 
Driving license: type B 
 Curriculum Vitae 
 Joana Silva 
 +351 91 9988777 # Joana.silva@gmail.com 
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3. Proof of registration with Eudravigilance  
 
3.1. Proof of registration of the QPPV 
 
Table 5 - QPPV Users List                                            
  
Organization 
ID 
Organization 
Organisazion 
Type 
QPPV 
QPPV 
Code 
Products as 
QPPV First 
Name 
Family 
Name 
Stala Pharma P  Affiliate 
Patrícia de 
Lurdes 
Douteiro 
Rodrigues 
58963 4 
Stala Pharma G  Affiliate 
Patrícia de 
Lurdes 
Douteiro 
Rodrigues 
58963 4 
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 3.2 Proof of registration of Stala Pharma 
 
Organization Information 
 
Organization Name: STALA PHARMA PHARMACEUTICAL PRODUCTS, SA. 
Organisation identifier: 
Trademark:  
Street: Rua Alexandre Pinto, nº105, 3º Esq ,  
City: Lisbon  
Postal code: 2800-039 
Area/state: Lisbon 
Country: Portugal 
 
Organization Name: STALA PHARMA GENERICS, SA. 
Organisation identifier: 
Trademark:  
Street: Rua Alexandre Pinto, nº105, 3º Esq.,  
City: Lisbon  
Postal code: 2800-039 
Area/state: Lisbon 
Country: Portugal 
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4. List of Delegated Tasks 
 4.1. Overview of delegated tasks by the QPPV 
  4.1.1. Internal delegation 
 
Table 6 - list of internal delegation 
Task Execution Revision on and by Delegation 
Fulfillment of the QPPV function QPPV - Deputy QPPV 
Preparation and submission to the 
authorities of PSURs addendum 
clinical overview and RMPs 
QPPV/Deputy 
QPPV/PV 
Officer 
Medical Consultant - 
Literature search 
Deputy 
QPPV/PV 
officer/PV 
Junior Officer 
Deputy Consultant QPPV 
Preparation and submission to the 
authorities: ICRs 
QPPV/Deputy 
QPPV/PV 
Officer 
Medical Consultant - 
Preparation of company-sponsored 
PASS 
QPPV Medical Consultant Deputy QPPV 
Overview of the safety profiles and 
any emerging safety concerns for 
the Stala Pharma’s drugs 
QPPV  
Deputy QPPV/PV 
Officer 
Provision of PhV training to the 
sales force 
QPPV  
Deputy QPPV/PV 
Officer 
Provision of PhV training to third 
country/distributors 
QPPV  Deputy QPPV 
Management and submission of 
safety variations 
QPPV Regulatory Director 
Deputy 
QPPV/Regulatory 
affairs 
department/PV 
Officer/PV Junior 
officer 
Management of post-Authorization 
commitments (regarding PhV 
issues) 
QPPV 
Regulatory affairs 
department 
Deputy QPPV/PV 
Officer 
Preparation and management of 
safety agreements 
QPPV 
Business 
development 
Department 
-- 
Monitoring the list published by 
EMA and security information 
Deputy 
QPPV/PV 
Officer/ PV 
Junior Officer 
-  QPPV 
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  4.1.2. External delegation 
 
Table 7- List of external delegation 
 
  4.1.3. Delegation to Distributors 
 
In cases where Stala Pharma Group is the marketing authorization holder, the 
pharmacovigilance department delegates tasks which are described in the field partner 
characterization/Delegated tasks. 
It can be found in the next page.
Delegated to             Task Product (s) 
Active 
substance 
Medion 
Farmaceutici S.A. 
Via S.P. Cototoinego, 
20 
56394 Milano 
- Undertaking signal detection. 
- To screen scientific literature. 
-Responsible for the 
development of PSURs and 
PBRER. 
Primax  
24 mg 
capsules 
Mesoglycan 
Abata Laboratories 
Lda 
Estrada da luz nº67 
Betapark, Edifício E, 
Alcabideche 2696-
365 Amadora 
-Abata is responsible for 
conducting worldwide 
literature review and local 
medical literature. 
-Abata is responsible for signal 
detection. 
-Abata is responsible for 
development of PSURs. 
Catalup 
200 mg 
capsules 
Fenofibrate 
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Table 8- Delegation activities to distributors 
 
 
Country 
Marketing 
authorisation 
Holder 
Partner/distri
butor 
Product AIM date Generics Delegated tasks Agreement 
Morocco  Stala Pharma G Morocco 
Distribution 
Ltd 
Paracetamol MG 
500 mg 
Tablet 
4-12-2015 Yes - National bibliographic search  
- Trainee in pharmacovigilance 
- Collecting and submitting ICRS 
Agreement 
number 
“1256” 
Mozambique Stala Pharma P Mozanpharma 
S.A. 
 
Rufen, 
ibuprofene, 600 
mg, film-coated 
tablets 
6-01-2016 No - National bibliographic search  
- Trainee in pharmacovigilance 
- Collecting and submitting ICRS 
Agreement 
number 
“1255” 
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5. Job description on Deputy-QPPV 
Table 9 - Function: Deputy - QPPV 
Framework 
OVERVIEW DESCRIPTION  
 
The main focus of the Deputy QPPV is to support the EU QPPV by fulfilling its role and 
responsibilities in order to ensure complete oversight of the Stala Pharma Pharmacovigilance 
System in terms of its structure and performance.  
The deputy QPPV must reside in the EEA and be available 24h/7 days per week. 
 
Competency requirements for the function performance 
 
Educated to Degree Level (Degree in Pharmacy, Life Sciences degree, PhD or equivalent 
education).  
 
Training and skills: 
 
Understands and maintains knowledge of PV regulations and guidelines.  
Understanding of the regulatory processes. 
Proven Pharmacovigilance experience, in particular in leading safety affiliate roles. 
Strong organizational and time management skills.  
Flexibility and ability to prioritize and manage multiple tasks in a challenging environment. 
Excellent communication skills.  
Highly proactive, self-motivated, professional and dedicated.  
Excellent written and speaking skills in English; other languages as an asset.  
Proficient PC skills: MS Office Suite including PowerPoint , Excel, Word and Outlook at 
intermediate level 
 
Experience 
Experience Minimum of 1 year working in Pharmacovigilance. 
 
Description of the main responsibilities 
1. Maintain the oversight of audits and PSUR quality and support the timely production and 
quality of the PSMF. 
 
2. Review and comments safety reports as PSURs, RMPs, PASS protocols and other scientific 
documents on behalf of the EU QPPV and with regard to quality, accuracy and scheduling. 
 
3. Assume the responsibilities of the EU QPPV when absent 
 
4. Have oversight, with the EU QPPV and relevant functions, of all safety-related matters 
pertaining to AAA products having a potential impact on EU and EEA and supports the 
monitoring of cumulative safety data, potential safety signal detection activities, evaluation of 
the benefit/risk profile, decisions on labelling changes, development of Pharmacovigilance 
plans and risk minimization plans. 
 
5. Support meetings with all affiliates, subcontractors and distributors. 
 
6. Meet regularly with the EU QPPV to ensure that there is adequate information exchange. 
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7. Fulfill any of the tasks of the EU QPPV as delegated 
8. Keep up-to-date with the relevant PV regulations and all PV policies and procedures of the 
company. 
 
9. Keep up-to-date with any changes to the global and European pharmacovigilance 
legislation and inform the department of any findings. 
 
10. Manage the process of case report validation and deadline for competent authority. 
 
11. Participate to audit to PV subcontractor, to initiate and follow up of all contracts with PV 
impact and to the validation of SmPC 
 
ORGANOGRAM
 
Remarks 
This function can be performed in the technician category. 
The functions described as corresponding only to nuclear performed on this date and it can be 
subject to change at any time. 
Function Holder 
 
Name: Joana Silva 
 
Signature: Joana Silva 
 
Date: 1/10/2016 
 
  
General Manager
Dr. Paulo Magalhães
Pharmacovigilance 
officer
João Sousa
Pharmacovigilance 
Junior officer
Bernardo de Araújo
Pharmacovigilance 
Department
Medical consultant
Dr. Eduardo Souto
QPPV
Patrícia Rodrigues Deputy-QPPV
Joana Silva
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6. Job description on QPPV 
Table 10 - Function: QPPV 
Framework 
OVERVIEW DESCRIPTION  
 
A QPPV has a central role focused on ensuring that the company meets all of its 
Pharmacovigilance responsibilities and that ultimately the safety of the public using the 
medicine is maximized. 
To have an overview of the safety profile for the products for which the company holds a 
Marketing Authorization. 
To implement and maintain a good Pharmacovigilance system. 
It is vital that the QPPV is available as a central point of contact to the competent authorities 
on a 24 hour basis and that an equally qualified and experienced deputy QPPV is appointed 
who can be contacted in their absence. 
The QPPV must reside in the EEA. 
 
Competency requirements for the function performance 
 
Education: degree in Medicine or Pharmaceutical Sciences with access to a doctor. 
 
Training and skills: 
 
Specific training in Pharmacovigilance, or practical experience proven. 
Good knowledge of the laws and regulations applicable to Pharmacovigilance. 
Good computer skills in the perspective of the user. 
Regular knowledge of the English language. 
Registered in the EudraVigilance database as QPPV. 
 
Experience 
 
QPPV who is experienced in pharmacovigilance (typically Master's degree and minimum two 
years of full time practical experience in pharmacovigilance) 
Description of the main responsibilities 
1. Establishing and maintaining/managing the MAH’s 
Pharmacovigilance 
Deputy QPPV 
2. The establishment and maintenance of a system which 
ensures that information referred to all suspected adverse 
reactions which are reported to the personnel of the Marketing 
Authorisation Holder, and to medical representatives, is 
collected and collated in order to be accessible at least at one 
point within the EU; 
Deputy QPPV 
3. Ensuring that there is a Detailed Description of PV Systems in 
place. 
Deputy QPPV 
4. Preparation of ICSRs (PSURs) and company-sponsored post- 
authorization safety studies (PASS). 
Deputy QPPV 
5. Continuous overall Pharmacovigilance evaluation during the 
post-authorization period. 
 
Deputy QPPV 
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6. Ensure that any request from the health agency is fully and 
promptly answered. 
7. Have an overview of the safety profiles and any emerging 
safety concerns for the company's drugs. 
Not delegate 
8. Preparing Pharmacovigilance reports as defined by 
regulations such as ICSRs, PSURs, PASS. 
Deputy QPPV 
9. The QPPV should also act as the Marketing Authorisation 
Holder’s contact point for Pharmacovigilance inspections or 
should be made aware by the Marketing Authorisation Holder 
of any inspection, in order to be available as necessary. 
10. The provision to the Competent Authorities of any other 
information relevant to the evaluation of the benefits and risks 
afforded by a medicinal product 
Deputy QPPV 
11. Participation on the performance of the risk plan 
management  
Deputy QPPV 
ORGANOGRAM 
 
Remarks 
This function can be performed in the technician category. 
The employee who performs the QPPV function has sufficient authority to influence the 
system of quality management of Phv, as well as system and performance of Phv activities. 
The functions described as corresponding only to nuclear performed on this date and it can be 
subject to change at any time. 
 
Function Holder 
 
Name: Patrícia de Lurdes Douteiro Rodrigues 
 
Signature: Patrícia de Lurdes Douteiro Rodrigues 
 
Date: 1/10/16 
 
General Manager
Dr. Paulo Magalhães
Pharmacovigilance 
officer
João Sousa
Pharmacovigilance 
Junior officer
Bernardo de Araújo
Pharmacovigilance 
Department
Medical consultant
Dr. Eduardo Souto
QPPV
Patrícia Rodrigues Deputy-QPPV
Joana Silva
Annex B 
PHARMACOVIGILANCE SYSTEM MASTER FILE 
BII48.2 rev01  Confidential Page 76 of 175 
Annex B 
1. List of Contracts and Agreements 
 
1.1. Internal contracts within the Stala Pharma Group. 
Table 11 - List of delegation activities 
From To PhV Agreement Concerning about 
Stala Pharma P Stala Pharma 
Services 
Agreement number 
4521 
All activities relating to: 
- Individual case safety report collection; 
- Evaluation; 
- Safety database case entry; 
- Periodic safety update report 
production; 
- Signal detection and analysis; 
- Risk management plan management; 
- Pre- and post-authorisation study 
management; 
- Management of safety variations to the 
terms of a marketing authorisation. 
Stala Pharma G Stala Pharma 
Services 
Agreement number 
4252 
All activities relating to: 
- Individual case safety report collection; 
- Evaluation;  
- Safety database case entry; 
- Periodic safety update report 
production; 
- Signal detection and analysis; 
- Risk management plan management; 
- Pre- and post-authorisation study 
management; 
- Management of safety variations to the 
terms of a marketing authorisation. 
 
 
   1.2. External Contractual Partners  
This contracts and agreements are performed and managed by a specific department 
(Business development). They have a particular site where the QPPV can access at any 
moment.   
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Annex C 
1. List of affiliates and third party contacts 
1.1 Companies within the Stala Pharma Group 
Table 12 - list of contacts  
Company Address Phone contact e-mail 
Stala Pharma - 
Pharmaceutical 
Products, S.A. 
Rua Alexandre Pinto, 
nº105, 3º esq, 2800-039 
Lisbon – Portugal 
+351 21 458 963 products@stalapharma.pt 
Stala Pharma - 
Generics, S.A. 
Rua Alexandre Pinto, 
nº105, 3º esq, 2800-039 
Lisbon – Portugal 
+351 21 458 963 generics@stalapharma.pt 
Stala Pharma - 
Services, S.A. 
Rua Alexandre Pinto, 
nº105, 3º esq, 2800-039 
Lisbon – Portugal 
+351 21 458 963 services@stalapharma.pt 
 
1.2 Partners 
Table 13 - list of contacts of partners 
Company Address Phone contact e-mail 
Medion 
Farmaceutici S.A. 
Via S.P. Cototoinego, 20 
56394 Milano 
+39 02 5953 6599 productsfarma@medion.it 
Abata 
Laboratories Lda 
Estrada da luz nº67 
Betapark, Edifício E, 
Alcabideche 2696-365 
Amadora 
+351 414 466 431 products@abatalaboratories.pt 
 
1.3. Distributors  
Table 14 - list of contacts of distributors 
Country Distributor PhV contact 
Partners 
characterization/delegated 
tasks 
PhV observation 
Morocco  Morocco 
Distribution 
Ltd 
 
m.r.c.@morp
harma.com 
- Bibliographic search  
- Trainee in PhV 
- Send a list of all valid ICSR  
- Send to us all 
information/queries/request 
derived from the RA 
Confirmation 
of the 
performing of 
the trainee in 
PhV  
Mozambique Mozanpharm
a S.A. 
 
pik@tresitap
harma.com 
- Bibliographic search  
- Trainee in PhV 
- Send a list of all valid ICSR  
Confirmation 
of the 
performing of 
the trainee in 
PhV 
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- Send to us all 
information/queries/request 
derived from the RA 
 
2. Collection of information – websites 
 
 2.1. Scientific literature reports 
  2.1.1. National 
 bibliovigilance.com 
 
  2.1.2. International  
 ncbi.nlm.nih.gov/pubmed 
 
  2.1.3. Monitoring of medical literature (EMA) 
 Eudravigilance.ema.europe.eu 
 
 2.2. Stala Pharma website 
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2. List of studies and programmes 
 
A Post-Authorisation Safety Study (PASS) to evaluate de effectiveness of the 
implementation of risk minimisation measures (RMMs) of isotretinoin is on-going. 
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Annex D  
1. Overview of Computerized systems 
 
Table 15 - Overview of Computerized systems 
System Functionality Location 
Validatio
n Status 
Validation 
document 
Fit for 
purpose 
Operational 
Responsibility 
Chance 
control 
managed 
by 
Chance 
control 
Document 
Back-up 
MS Excel® Safety database to 
collection ICSRs  
Local server,  
Lisbon 
Portugal 
N/A N/A Yes Microsoft Excel Microsoft 
Excel 
representati
ve 
N/A N/A 
EudraVigilance Reporting ICSRs to the 
Agency  
EMA servers N/A N/A yes EMA EMA N/A N/A 
RegistMed Database for storage and 
tracking of information 
received via Customer 
Care Service (SAC) namely, 
Medical Information 
requests or enquiries, 
product technical or 
quality complaints and 
individual Case Safety 
Report. 
Local server,  
Lisbon 
Portugal 
N/A 
 
  
N/A yes Salesforce Sales 
manager 
representati
ve 
N/A N/A 
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System Functionality Location 
Validatio
n Status 
Validation 
document 
Fit for 
purpose 
Operational 
Responsibility 
Chance 
control 
managed 
by 
Chance 
control 
Document 
Back-up 
eCTD -Generation of PSUR structure  
for electronic submission 
-Generation of RMP structure 
for submission 
-Generate the structure of all 
documents needed in PhV 
activities.  
Local 
server,  
Lisbon 
Portugal 
N/A N/A yes Extedo Extedo N/A Daily 
Weekly 
Monthly 
Yearly 
 
eSubmission 
WebClient 
Electronic submission of 
PSURs 
EMA 
servers 
N/A N/A yes EMA EMA N/A N/A 
Spotyver Plus Documental management 
system  
Local 
server,  
Lisbon 
Portugal 
Validate Validate 
document 
yes CHRin 
Stala IT 
CHRin 
Stala IT 
MOD001 Daily 
Weekly 
Monthly 
Yearly 
EV WebTrader To perform and update of 
product information into the 
XEVMPD 
EMA 
servers 
N/A N/A yes EMA EMA N/A N/A 
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2. Overview of Databases 
  
     Table 16 - overview of databases 
Database Functionality Responsibility Documents identification 
Contractual partners 
List of contractual and agreements with PhV 
impact 
Identification of agreements for the PSMF 
purposes 
Business Department and 
Pharmacovigilance Department 
Annex B 
(BII48.2 rev01) 
MOD1001 
Affiliates and third party List of affiliates and third party contracts 
Regulatory Affairs Department 
and Pharmacovigilance 
Department 
Annex C 
(BII48.3 rev01) 
MOD1002 
Products List of products covered by the PSMF 
Regulatory Affairs Department 
 
Annex H 
(BII48.8 rev01) 
MOD1003 
PSUR and addendum to 
the clinical overview 
Management of PSURs and Addendum to the 
clinical overview submission dates 
Pharmacovigilance Department MOD1004 
Reconciliation data in 
PhV 
Management of periodicity with partners for  
reconciliation purposes 
safety data exchanged during the concerned 
period of time 
Pharmacovigilance Department MOD1005 
Signal management 
Management of risks and safety signal. 
Source of information and the signal status (on 
going, under monitoring, closed). 
Scheduling of signal management reports. 
Existence of Risk Management Plan for each 
product. 
Pharmacovigilance Department MOD1006 
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Database Functionality Responsibility Documents identification 
Procedures Deviations 
Management 
Management of procedures deviations Pharmacovigilance Department MOD1007 
Management of the 
information at XEVMPD 
Management, submission and update of product 
information into the XEVMPD (according with 
article 57) 
Pharmacovigilance Department MOD1008 
Safety Variations 
Scheduling of safety variations submission dates 
Management of approval dates 
Identification of the person responsible for each 
safety variations 
Identification of the person responsible for each 
safety variation submitted 
Pharmacovigilance Department MOD1009 
Bibliographic Search 
Management of Bibliographic Search 
Identification of ICSRs or relevant information for 
each active substance marketed by Stala Pharma 
Group in literature 
Pharmacovigilance Department MOD1010 
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Annex E 
 
Pharmacovigilance Process and Written Procedures 
 
The documented procedural documents include: 
 
1. Standard operating procedures (SOPs) 
2. Summary of the Applicant´s Pharmacovigilance System 
3. Pharmacovigilance System Master File 
4. Models
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1. Standard operating procedures (SOPs) 
 
Table 17 - List of Standard operation Procedures 
Name/version Title Date Validity Owner 
PGE123rev03 Job description 09-10-2015 09-10-2018 Catarina Mendes 
Quality Person 
PGE124rev05 Organization chart 09-10-2015 09-10-2018 Catarina Mendes 
Quality Person 
PGE125rev01  Pharmacovigilance System 
Quality Management 
01-10-2016 01-10-2019 Patrícia Rodrigues 
QPPV 
PGE126rev10 Training 10-10-2016 10-10-2019 Catarina Mendes 
Quality Person 
PGE127rev02 Research of Literature 10-10-2016 10-10-2019 Patrícia Rodrigues 
QPPV 
PGE128rev03 Periodic safety Update 
reports 
10-10-2016 10-10-2019 Patrícia Rodrigues 
QPPV 
PGE129rev05 Signal Management and 
Risk-Benefit Evaluation 
01-09-2016 01-09-2019 Patrícia Rodrigues 
QPPV 
PGE130rev02 Pharmacovigilance System 
Master File Management 
01-09-2016 01-09-2019 Patrícia Rodrigues 
QPPV 
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Name/version Title Date Validity Owner 
PGE131rev01 Risk Management Plan 01-09-2016 01-09-2019 
Patrícia Rodrigues 
QPPV 
PGE132rev03 
Response to requests for 
information 
01-09-2016 01-09-2019 
Patrícia Rodrigues 
QPPV 
PGE133rev03 
Communication of relevant 
information 
01-09-2016 01-09-2019 
Patrícia Rodrigues 
QPPV 
PGE134rev02 
Management of solicited and 
unsolicited safety information 
01-09-2016 01-09-2019 
Patrícia Rodrigues 
QPPV 
PGE135rev03 Safety variations 01-09-2016 01-09-2019 
Patrícia Rodrigues 
QPPV 
 
2. Summary of the Applicant’s Pharmacovigilance System 
 
Table 18 -  List of Summary of the Applicant’s Pharmacovigilance System 
Name/version Title Date Validity Owner 
PGE134rev02 
Summary of the Applicant’s 
Pharmacovigilance System 
Stala Pharma - Pharmaceutical 
Products, S.A. 
01-09-2016 01-09-2019 
Patrícia Rodrigues 
QPPV 
PGE135rev03 
Summary of the Applicant’s 
Pharmacovigilance System 
Stala Pharma - Generics, S.A. 
01-09-2016 01-09-2019 
Patrícia Rodrigues 
QPPV 
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3. Pharmacovigilance System Master File  
 
Table 19 - List of PSMF’documents 
Name/version Title Date Validity Owner 
IIB41.1rev00 Cover page 01-09-2016 01-09-2019 
Patrícia Rodrigues 
QPPV 
IIB41.2rev00 Quality Person for Pharmacovigilance 01-09-2016 01-09-2019 
Patrícia Rodrigues 
QPPV 
IIB42rev00 Organisation Structure 01-09-2016 01-09-2019 
Patrícia Rodrigues 
QPPV 
IIB43rev00 The sources of Safety Data 01-09-2016 01-09-2019 
Patrícia Rodrigues 
QPPV 
IIB44rev00 Computerised Systems and Databases 01-09-2016 01-09-2019 
Patrícia Rodrigues 
QPPV 
IIB45rev00 Pharmacovigilance Process 01-09-2016 01-09-2019 
Patrícia Rodrigues 
QPPV 
IIB46rev00 Pharmacovigilance System Performance 01-09-2016 01-09-2019 
Patrícia Rodrigues 
QPPV 
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Name/version Title Date Validity Owner 
IIB47rev00 Quality system 01-09-2016 01-09-2019 
Patrícia Rodrigues 
QPPV 
IIB48.1 rev00 
Annex A - List of delegated tasks  
Annex A – CV of QPPV 
Annex A – CV of Deputy QPPV 
Annex A - Job description of QPPV 
Annex A - Job Description of Deputy QPPV  
Annex A – Proof of registration with 
EudraVigilance 
01-09-2016 01-09-2019 
Patrícia Rodrigues 
QPPV 
IIB48.2 rev01 Annex B – List of contracts and agreements  01-09-2016 01-09-2019 
Patrícia Rodrigues 
QPPV 
IIB48.3 rev00 
Annex C - List of affiliates and third party 
contacts 
Annex C – List of studies and programmes 
01-09-2016 01-09-2019 
Patrícia Rodrigues 
QPPV 
IIIB48.4 rev00 
Annex D- Overview of computerised systems 
and Databases 
Annex D – Overview of Databases 
01-09-2016 01-09-2019 
Patrícia Rodrigues 
QPPV 
IIB48.5 rev00 Annex E – List  of Procedural documents 01-09-2016 01-09-2019 
Patrícia Rodrigues 
QPPV 
IIB48.6 rev00 
Annex F – List of performance indicators  
Annex F – Compliance with submission 
timelines – past year 
01-09-2016 01-09-2019 
Patrícia Rodrigues 
QPPV 
IIB48.7 rev00 Annex G – List of all scheduled and completed 
audits (5-year history) 
01-09-2016 01-09-2019 
Patrícia Rodrigues 
QPPV 
IIB48.9 rev01 
Annex I – Logbook-Date, person, nature of the 
change 
Annex I – History of changes in Annex A-H 
01-09-2016 01-09-2019 
Patrícia Rodrigues 
QPPV 
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4. Models 
 
Models to be used in pharmacovigilance activities. 
An overview of databases is identified in BIIB4.4 rev00 (Annex D- Computerised Systems and Databases). 
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Annex F 
Performance Indicators used in Stala Pharma pharmacovigilance system 
 
Table 20 - list of indicators 
Type of Performance Indicator Performance Indicator 
ADR/AE input management 
 Rate (100%) of received ADR/AE  
 Average time needed for validation decision 
Management of valid ADR 
 Rate (100%) of valid ADR/AE  
 Rate (100%) of valid ADR occurred in EU 
 Rate (100%) serious ADR 
 Rate (100%) non-serious ADR 
 Rate (100%) of compliance on notification 
process 
 Rate (100%) of compliance on notification 
deadlines 
Literature Research 
 Rate (90%) of literature researches 
 Rate (90%) of processed literature research 
cases 
 Rate (90%) of valid ADR originated from 
literature research 
PSUR 
 Rate (100%) of compliance on PSUR 
submissions 
 Rate (100%) of compliance on PSUR 
submission deadlines 
 Average time needed for PSUR submission 
upon Data Lock Point (± Standard Deviation) 
Risk Management Plan 
 Rate (100%) of medical products with RMP 
 Rate (100%) of RMP with “Risk minimization 
measures” 
 Rate (100%) of compliance on RMP updates 
 Rate (100%) of compliance on RMP updates 
deadlines 
Safety variations 
 Rate (100%) of safety variations 
 Rate (100%) of compliance on safety 
variations submission deadlines 
Security measures 
 Number of security measures per year 
 Number of DHCP per year 
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Compliance with submission timelines – past year 
 
The objective of this annex F is to present current results of performance assessment in relation to the indicators regarding 2016. 
 
1. ADR/AE input management 
The target for ADR/AE input management indicator was 100 % according to PGE129rev05. 
Table 21 - Data for measurement of the performance indicator 
Number of received ADR/AE Time need for validation Conformity 
5 2 days Complies 
 
 
2. Management of valid ADR 
The target for Management of valid ADR indicator was 100 % according to PGE129rev05. 
Table 22 - Data for measurement of the performance indicator 
Number of valid 
ADR/AE 
Number of valid 
ADR in EU 
Number of 
serious ICSRs 
Number of non-
serious 
ICSRs 
ICSRs reported to the 
Authority 
ICSRs reported to the 
Authority within the 
legal deadline 
Result 
2 2 - 2 2 2 100% 
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Table 23 -Data for measurement of the performance indicator 
Wordwide ID number Day 0 
Data of transmission to the 
authorities/ conformity 
Way to transmission ACK/conformity 
Pt-stalapharma-2016-02-5236 06-02-2016 08-02-2016 
complies 
gateway 01 
complies 
Pt-stalapharma-2016-02-5237 02-09-2016 05-02-2016 
complies 
gateway 02 
complies 
 
3. Submission of PSURs (PSURs reporting timelines) 
The target for submission of PSURs indicator was 100 %. The goal was reached in 2016. 
Table 24 - Data for measurement of the performance indicator 
Total od PSURs Scheduled 
in 2016 
PSURs submitted 
PSURs submitted within 
the legal deadline 
PSURs reported with ACK 01 Result 
2 2 2 2/2 (e-submission) 100% 
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Table 25- Data for measurement of the performance indicator 
Medicine Data lock point 
Date scheduled for 
submission 
Data of submission to the 
authorities/ conformity 
ACK (for e-submission)/conformity 
Isotretinoin 06-05-2016 06-08-2016 07-08-2016 
01 
complies 
Rufen 03-10-2016 03-11-2016 05-11-2016 
01 
complies 
 
 
4. Submission of RMPs (RMP reporting timelines) 
The target deadline for submission of RMPs was 100% according to PGE131rev01. 
 
Table 26 - Data for measurement of the performance indicator 
Total of RMPs Schedule 
in 2016 
Medicinal product RMPs submitted 
RMPs submitted within 
the legal deadline 
RMP with “Risk 
minimization 
measures” 
Result 
1 Paracetamol MG 1 1 No 100 % 
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 5. Safety variations (safety variations submitted within the legal deadline) 
The target deadline for submission of safety variations indicator was 100 % according to PGE135rev03 
Table 27 - Data for measurement of the performance indicator 
Total of safety variations submitted in 2016 
Safety variations submitted within the legal 
deadline 
Result 
3 3 100% 
 
Table 28 - Data for measurement of the performance indicator 
Medicine 
Pharmaceutical 
form 
Dosage 
Variation 
type 
Variation 
Type 
Data scheduled for 
submission 
Data of submission to the 
authorities/conformity 
Rufen 
(Ibuprofeno) 
Film-coated tablets 600 mg IB C.I.1.a) 12-02-2016 
10-02-2016 
complies 
Omeprax 
(omeprazole) 
Gastro-resistant 
capsules 
20 mg IB C.I.z 11-05-2016 
27-04-2016 
Complies 
Isotretinoína MG Soft capsules 10 mg IAIN C.I.8) 12-12-2016 
27-04-2016 
Complies 
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6. Bibliographic Research (Bibliographic research performed within legal timelines) 
The target for bibliographic research performed indicator was 90 % according to PGE127rev02 
 
Table 29 - Data for measurement of the performance indicator 
Number of literature 
researches 
Number of processed 
literature research cases 
Number of valid originated 
from literature cases 
Result 
52 10 10 100 % 
 
7. Security measures 
 
Table 30 - Data for measurement of the performance indicator 
Number of security measures per year Number of DHCP per year 
1 1 
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Annex G 
1 Strategic Audit program 
 
Table 31 - Strategic Audit program 
 
2017 to 2021 
Auditee and /or 
process to be audited 
Level 
of risk 
Justification for 
level of risk 
Last audit 
date 
Period to be 
covered 
Products 
Mozanpharma S.A. 
- National bibliographic 
search  
-Trainee in 
pharmacovigilance 
- collecting and 
submitting ICRS 
Low 
Product market in 
Mozambique 
Stala Pharma is 
MAH of the 
products referred 
Not 
applicable 
January 2016 
to (to be 
defined) 
Paracetamol 
MG, 500 mg, 
tablet 
Morocco Distribution 
Ltd 
- National bibliographic 
search  
-Trainee in 
pharmacovigilance 
-Collecting and 
submitting ICRS 
Low 
Product market in 
Mozambique 
Stala Pharma is 
MAH of the 
products referred 
Not 
applicable 
January 2016 
to (to be 
defined) 
Rufen, 
ubuprofene, 
600 mg, film-
coated tablets 
Pharmacovigilance 
system and processes of 
Stala Pharma Group, 
including quality system 
for pharmacovigilance 
activities 
High 
Stala Pharma is 
the MAH and has 
to audit the 
system every 2 
years. 
December 
2016 
December 
2016 to 
December 
2018 
All product 
which Stala 
Pharma is a 
MAH 
 
Pharmacovigilance 
system and processes of 
Stala Pharma Group, 
including quality system 
for pharmacovigilance 
activities 
High 
Stala Pharma is 
the MAH and has 
to audit the 
system every 2 
years. 
Not know 
yet 
December 
2018 to 
December 
2020 
All product 
which Stala 
Pharma is a 
MAH 
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Table 32- Strategic Audit program 
2017 to 2021 
Auditee and /or 
process to be audited 
Level 
of risk 
Justification for 
level of risk 
Last audit 
date 
Period to be 
covered 
Products 
Medion Farmaceutici 
S.A. 
- Process for undertaking 
signal detection. 
- Process to screen 
scientific literature. 
- Process for the 
development of PSURs 
and PBRER. 
High 
Stala Pharma is 
MAH of the 
product referred  
Not 
applicable 
December 
2017 to 
December 
2019 
 
Primax  
24 mg 
capsules 
Abata Laboratories Lda 
-Process for conducting 
worldwide literature 
review and local medical 
literature. 
-Process for signal 
detection. 
-Process for development 
of PSURs. 
High 
Stala Pharma is 
MAH of the 
product referred 
Not 
applicable 
December 
2018 to 
December 
2020 
Catalup 
200 mg 
capsules 
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2. Tactical level audit planning – 1 year 
 
Table 33 - Tactical level audit planning 
 Proposed 
dates 
Duration Auditee/process to 
be audited 
Audit 
team 
Confirmed by Date of 
confirmation 
December 
2017 
4 hours - Process of National 
bibliographic search  
-Process of trainee in 
pharmacovigilance 
- Process of collecting 
and submitting ICRS 
QPPV 
and  
Deputy- 
QPPV 
Morocco 
Distribution 
Ltd 
Not yet 
available  
December 
2017 
4 hours - Process of National 
bibliographic search  
-Process of trainee in 
pharmacovigilance 
- Process of collecting 
and submitting ICRS 
QPPV 
and  
Deputy- 
QPPV 
Mozanpharma 
S.A. 
 
Not yet 
available 
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Annex H - List of Products at Stala Pharma Group  
Table 34 - List of medicinal products 
Marketing 
authorisation 
Holder 
Product 
name 
Active 
substance 
AIM 
date 
Type of 
procedure 
Generics Brand 
Risk 
management 
Plan 
Product 
additional 
monitoring 
Additional risk 
minimisation  
measures 
Stala Pharma G 
Paracetamol MG 
500 mg 
Tablet 
Paracetamol 
4-12-
2015 
National No yes yes No No 
Stala Pharma G 
Isotretinoin MG 
10 mg 
Soft capsule 
Isotretinoin 
xx-xx-
xxxx 
National yes No yes No 
Yes 
PPG 
Stala Pharma P 
Rufen 
600 mg 
Film-coated tablet 
Ibuprofene 
6-05-
2012 
National No yes Yes No No 
Stala Pharma P 
Omeprax 
20 mg 
Gastro-resistant capsules 
Omeprazole 
6-04-
2005 
National No Yes No No No 
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Annex I 
1. History of changes in Annex A-H 
 
The contents of the annexes belonging to the Pharmacovigilance System Master File, from IIB4 up to 
IIB48, are inserted into the Documental Data Base. 
 
The annexes listed in the table below show the last changes occurred in this Annex of PSMF. 
Table 35 - List of last changes in Annexes 
Annex of 
the PSMF 
Name of 
document 
Documen
t 
Location of the 
document 
Location of the 
last copy 
Responsible 
for the 
change 
Annex C - 
List of 
affiliates and 
third party 
contacts 
Export 
management 
Doc123 
Contract 
management, 
Doc123 
Regulatory 
department 
Susana Pinto 
Annex B- List 
of contracts 
and 
agreements 
List of contracts 
and agreements 
relevant to 
pharmacovigilance 
Doc126 
List of contracts and 
agreements 
relevant to 
pharmacovigilance, 
Doc126 
Pharmacovigilanc
e Department 
Patrícia 
Rodrigues 
Annex H – 
List of 
products 
General map Doc125 
General map, 
Doc125 
Regulatory 
department 
Carla Paiva 
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2. Logbook (Date, person, nature of the change) 
 
The logbook is a detailed table where it is described all the main procedures in 
Pharmacovigilance, as well as the date, signature and the name of the person who did it.  
 
If there were changes to the normal procedure, it is required justification and the 
identification of the collaborator. 
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EU Risk Management Plan for Isotretinoin Generics®  
Isotretinoin 
 
RMP version to be assessed as part of this application:  
RMP Version number: 0.1 
Data lock point for this RMP: 30-05-2017 
Date of final sign off:  25-08-2017 
Rationale for submitting an updated RMP: Not applicable  
Summary of significant changes in this RMP: Not applicable 
 
QPPV name: Patrícia de Lurdes Douteiro Rodrigues 
QPPV signature: Patrícia de Lurdes Douteiro Rodrigues 
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Part I: Product(s) Overview 
Table 36 - Part I.1 – Product Overview 
Active substance(s)  
(INN or common name) 
Isotretinoin 
Pharmacotherapeutic 
group(s) (ATC Code) 
D10BA01 
Marketing Authorisation 
Holder 
Stala Pharma Generics 
Medicinal products to which 
this RMP refers 
1 
Invented name(s) in the 
European Economic Area 
(EEA) 
Not applicable 
Marketing authorisation 
procedure  
National 
Brief description of the 
product 
 
Chemical class  
Isotretinoin belongs to the pharmacotherapeutic group of antiacne 
preparations for systemic use. 
Isotretinoin is a stereoisomer of all-trans retinoic acid (tretinoin). 
 
Summary of mode of action  
Its exact mechanism of action has not yet been elucidated in detail, but 
it has been established that the improvement observed in the clinical 
picture of severe acne is associated with suppression of sebaceous 
gland activity and a histologically demonstrated reduction in size of the 
sebaceous glands. Furthermore, a dermal anti-inflammatory effect of 
isotretinoin has been established. 
Hyperlink to the Product 
Information 
Isotretinoin Generics 10/0000/m1/eu/13-pi/13.1-pil/Portugal 
Indication(s) in the EEA 
 
Severe forms of acne (such as nodular and conglobate acne or acne at 
risk of permanent scarring) resistant to adequate courses of standard 
therapy with systemic antibacterial and topical therapy. 
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Dosage in the EEA 
 
Isotretinoin should only be prescribed by or under the supervision of 
physicians with expertise in the use of systemic retinoids for the 
treatment of severe acne and a full understanding of the risks of 
isotretinoin therapy and monitoring requirements. 
Isotretinoin should only be prescribed by or under the supervision of 
physicians with expertise in the use of systemic retinoids for the 
treatment of severe acne and a full understanding of the risks of 
isotretinoin therapy and monitoring requirements. 
Adults including adolescents and the elderly: 
Isotretinoin therapy should be started at a dose of 0.5 mg/kg daily. The 
therapeutic response to isotretinoin and some of the adverse effects are 
dose-related and vary between patients. This necessitates individual 
dosage adjustment during therapy. For most patients, the dose ranges 
from 0.5-1.0 mg/kg per day. 
Long-term remission and relapse rates are more closely related to the 
total dose administered than to either duration of treatment or daily 
dose. It has been shown that no substantial additional benefit is to be 
expected beyond a cumulative treatment dose of 120-150 mg/kg. The 
duration of treatment will depend on the individual daily dose. A 
treatment course of 16-24 weeks is normally sufficient to achieve 
remission. 
In the majority of patients, complete clearing of the acne is obtained 
with a single treatment course. In the event of a definite relapse a further 
course of isotretinoin therapy may be considered using the same daily 
dose and cumulative treatment dose. 
As further improvement of the acne can be observed up to 8 weeks 
after discontinuation of treatment, a further course of treatment should 
not be considered until at least this period has elapsed. 
Patients with renal impairment 
In patients with severe renal insufficiency treatment should be started 
at a lower dose (e.g. 10 mg/day). The dose should then be increased 
up to 1 mg/kg/day or until the patient is receiving the maximum tolerated 
dose (see section 4.4). 
Paediatric population 
Isotretinoin is not indicated for the treatment of prepubertal acne and is 
not recommended in patients less than 12 years of age due to a lack of 
data on efficacy and safety. 
Patients with intolerance 
In patients who show severe intolerance to the recommended dose, 
treatment may be continued at a lower dose with the consequences of 
a longer therapy duration and a higher risk of relapse. In order to 
achieve the maximum possible efficacy in these patients the dose 
should normally be continued at the highest tolerated dose. 
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Pharmaceutical form(s) and 
strengths 
 
Soft capsules  
10 mg 
Is/will the product be subject 
to additional monitoring in 
the EU?       
No 
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Part II: Safety specification 
 
Part II: Module SI - Epidemiology of the indication(s) and target 
population(s) 
This module is not applicable for RMPs submitted with initial marketing authorisation 
applications involving Generic medicinal products. Isotretinoin Generics is a generic 
medicinal product, so this module is not applicable. 
 
Part II: Module SII - Non-clinical part of the safety specification 
This module is not applicable for RMPs submitted with initial marketing authorisation 
applications involving Generic medicinal products. Isotretinoin Generics is a generic 
medicinal product, so this module is not applicable. 
 
Part II: Module SIII - Clinical trial exposure   
This module is not applicable for RMPs submitted with initial marketing authorisation 
applications involving Generic medicinal products. Isotretinoin Generics is a generic 
medicinal product, so this application is not applicable.  
 
Part II: Module SIV - Populations not studied in clinical trials 
This module is not applicable for RMPs submitted with initial marketing authorisation 
applications involving Generic medicinal products. Isotretinoin Generics is a generic 
medicinal product, so this module is not applicable.  
 
Part II: Module SV - Post-authorisation experience    
This module is not applicable in the same situations as Module SIV, described above. 
 
Part II: Module SVI - Additional EU requirements for the safety 
specification       
 
Potential for misuse for illegal purposes 
This module is not applicable in the same situations as Modules SIV-SV as described 
above. 
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Part II: Module SVII - Identified and potential risks  
The originator product does not have an RMP but the safety concerns of the substance 
are published on the CMDh website, therefore this module is not applicable. 
  
       RISK MANAGEMENT PLAN 
Vs (1.01/2017) Confidential Page 110 of 175 
 
Part II: Module SVIII - Summary of the safety concerns 
 
Table 37 - SVIII.1: Summary of safety concerns 
Summary of safety concerns 
Important identified 
risks 
Teratogenicity 
Psychiatric Disorders- including depression, suicidality and 
anxiety 
Eye disorders including corneal opacities, reduced night 
vision and keratitis 
Musculoskeletal and connective tissue disorders including 
bone changes and rhabdomyolysis 
Severe skin reactions (including SJS and TEN) 
Benign intracranial hypertension 
Severe increase in triglyceride levels, sometimes 
associated with acute pancreatitis 
Severe allergic reactions 
Important potential 
risks 
Gastrointestinal disorders including inflammatory bowel 
disease 
Missing information Not applicable 
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Part III: Pharmacovigilance Plan (including post-authorisation 
safety studies) 
 
 III.1 Routine pharmacovigilance activities    
 
The routine pharmacovigilance is the primary set of activities required to fulfil the legal 
requirements for pharmacovigilance contained in Directive 2001/83/EC and Regulation 
(EC) No 726/2004.  
 
All the routine pharmacovigilance activities for isotretinoin are performed by Stala 
Pharma following processes and procedures that are summarized in the current version 
of the Pharmacovigilance System Master File. This routine pharmacovigilance includes 
the following: 
- Systems and processes that ensure that information about all suspected adverse 
reactions that are reported to the personnel of the company are collected and 
collated in an accessible manner; 
- The preparation of reports for regulatory authorities:  
  o Expedited adverse drug reaction (ADR) reports;  
o Periodic Safety Update Reports (PSURs). 
- Continuous monitoring of the safety profile of approved products including signal 
detection, issue evaluation, updating of labelling, and liaison with regulatory 
authorities;  
- Other requirements, as defined by local regulations.  
 
 III.2 Additional pharmacovigilance activities  
 
In order to assist prescribers, pharmacists and patients, the Marketing Authorisation 
Holder provides educational materials to reinforce the warnings about the teratogenicity, 
psychiatric disorders including depression and severe lipids disorders including 
pancreatitis. Therefore, as an additional pharmacovigilance activity we propose a Post-
Authorisation Safety Study (PASS) to evaluate de effectiveness of the implementation of 
these risk minimisation measures (RMMs). 
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The Planned pharmacovigilance activities by safety concerns are presented below: 
 
 Teratogenicity and drug exposure during pregnancy 
- Routine pharmacovigilance 
- Enhanced pharmacovigilance 
  (Close monitoring, aggregate analysis in PSUR, signal detection, specific post-
marketing notification form and documentation of cases) 
 
 Depression, suicide, suicide attempt, suicide ideation 
- Routine pharmacovigilance 
- Enhanced pharmacovigilance 
  (Close monitoring, aggregate analysis in PSUR, signal detection, specific post-
marketing notification form and documentation of cases) 
 
 Severe lipid metabolism disorders with acute pancreatitis 
- Routine pharmacovigilance 
- Enhanced pharmacovigilance 
  (Close monitoring, aggregate analysis in PSUR, signal detection, documentation of 
cases). 
 
 III.3 Summary Table of additional Pharmacovigilance 
activities  
 
Table 38 – Summary of additional PhV activities 
Safety concerns Planned Action (s) 
Important identified risks 
Teratogenicity 
 
Psychiatric Disorders- including 
depression, suicidality and anxiety 
 
Severe increase in triglyceride levels, 
sometimes associated with acute 
pancreatitis 
Routine Pharmacovigilance  
measures described above 
 
Additional pharmacovigilance activities 
In order to assist prescribers, pharmacists 
and patients, the Marketing Authorisation 
Holder provides educational materials to 
reinforce the warnings about the 
teratogenicity, psychiatric disorders including 
depression and severe lipids disorders 
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including pancreatitis. Therefore, as an 
additional pharmacovigilance activity we 
propose a Post-Authorisation Safety Study 
(PASS) to evaluate de effectiveness of the 
implementation of these risk minimisation 
measures (RMMs) 
Official title: Evaluation of the Effectiveness 
of Risk Minimisation Measures: A Joint PASS 
Survey and Drug Utilisation Study among 
Health Care Professionals to Assess their 
Knowledge and Attitudes on Prescribing 
Conditions of isotretinoin in France, Germany, 
Portugal, Spain, Sweden and United Kingdom 
Study type: Observational study 
Brief description of the study: Evaluation of 
the Effectiveness of Risk Minimisation 
Measures: A Joint PASS Survey and Drug 
Utilisation Study among Health Care 
Professionals to Assess their Knowledge and 
Attitudes on Prescribing Conditions of 
isotretinoin in France, Germany, Portugal, 
Spain, Sweden and United Kingdom 
EU RMP category 3 (required) 
Start date of data collection 31/03/2016 to 
31/08/2017 
Date of final study report 09/09/2018 
 
Severe skin reactions 
 
Eye disorders including corneal 
opacities, reduced night vision and 
keratitis 
 
Musculoskeletal and connective 
tissue disorders including bone 
changes and rhabdomyolysis 
 
Routine Pharmacovigilance  
measures described above 
 
Additional pharmacovigilance activities 
Not applicable  
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Part IV: Plans for post-authorisation efficacy studies    
Not applicable. 
 
 
 
Part V: Risk minimisation measures (including evaluation of the 
effectiveness of risk minimisation activities) 
Severe skin reactions (including SJS 
and TEN) 
 
Benign intracranial hypertension 
 
Severe allergic reactions 
Important potential risks 
Gastrointestinal disorders including 
inflammatory bowel disease 
Routine Pharmacovigilance  
measures described above 
 
 
Additional pharmacovigilance activities  
Not applicable 
Missing information 
Not applicable Routine Pharmacovigilance  
Not applicable 
 
Additional pharmacovigilance activities  
Not applicable 
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Risk Minimisation Plan  
V.1. Routine Risk Minimisation Measures (RMM) 
Table 39 - Part V.1: Description of routine RMMs by safety concerns 
Safety concern Routine risk minimisation activities 
Teratogenicity Routine risk communication: 
Provide in SmPC section 4.3. Contraindications 
Isotretinoin is contraindicated in women who are pregnant or 
breastfeeding (see section 4.6). 
Isotretinoin is contraindicated in women of childbearing potential 
unless all of the conditions of the Pregnancy Prevention Programme 
are met (see section 4.4). 
Provide in SmPC section 4.4. Special warnings and precautions 
for use 
Pregnancy Prevention Programme 
This medicinal product is TERATOGENIC  
Isotretinoin is contraindicated in women of childbearing potential 
unless all of the following conditions of the Pregnancy Prevention 
Programme are met: 
- She has severe acne (such as nodular or conglobate acne or acne 
at risk of permanent scarring) resistant to adequate courses of 
standard therapy with systemic anti-bacterials and topical therapy 
(see section 4.1).  
- She understands the teratogenic risk, if becoming pregnant.  
- She understands the need for rigorous follow-up, on a monthly 
basis. 
- A pregnancy test is mandatory in each follow-up visit. 
- She understands and accepts the need for effective contraception, 
without interruption, 1 month before starting treatment, throughout 
the duration of treatment and 1 month after the end of treatment. 
Two complementary forms of contraception including a barrier 
method, e.g. a condom or a diaphragm, should be used. Calendar-
based contraceptive methods or Coitus interrupts shall not be 
used due its lack of effectiveness. 
- Even if she has amenorrhea she must follow all of the advice on 
effective contraception. 
 - She should be capable of complying with effective contraceptive 
measures.  
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- She is informed and understands the potential consequences of 
pregnancy and the need to rapidly consult a doctor if there is a risk 
of pregnancy.  
- She understands the need and accepts to undergo pregnancy 
testing before, during and 5 weeks after the end of treatment. 
- She has acknowledged that she has understood the hazards and 
necessary precautions associated with the use of isotretinoin. 
These conditions also concern women who are not currently 
sexually active unless the prescriber considers that there are 
compelling reasons to indicate that there is no risk of pregnancy. 
Contraception  
Female patients must be provided with comprehensive information 
on pregnancy prevention and should be referred for contraceptive 
advice if they are not using effective contraception.  
As a minimum requirement, female patients at potential risk of 
pregnancy must use two effective method of contraception. 
Contraception must include a barrier method, and start at least 4 
weeks before the treatment, during the treatment and should be 
continued for at least 1 month after stopping treatment with 
isotretinoin, even in patients with amenorrhea. 
Calendar-based contraceptive methods or Coitus interrupts shall not 
be used due its lack of effectiveness. 
Provide in SmPC section 4.6 - Fertility, pregnancy and lactation 
Pregnancy  
Pregnancy is an ABSOLUTE contraindication to treatment with 
isotretinoin (see section 4.3). If pregnancy does occur in spite of 
these precautions during treatment with isotretinoin or in the month 
following, there is a great risk of very severe and serious 
malformation of the foetus. Even minimal doses of isotretinoin 
administered during very short periods, may have teratogenic 
effects. 
The foetal malformations associated with exposure to isotretinoin 
include central nervous system abnormalities (hydrocephalus, 
cerebellar malformation/abnormalities, microcephaly), facial 
dysmorphia, cleft palate, external ear abnormalities (absence of 
external ear, small or absent external auditory canals), eye 
abnormalities (microphthalmia), cardiovascular abnormalities 
(conotruncal malformations such as tetralogy of Fallot, transposition 
of great vessels, septal defects), thymus gland abnormality and 
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parathyroid gland abnormalities. There is also an increased 
incidence of spontaneous abortion.  
If pregnancy occurs in a woman treated with isotretinoin, treatment 
must be stopped, and the patient should be referred to a physician 
specialised or experienced in teratology for evaluation and advice. 
Associated wording is included in the PIL. 
Labelling also warning about the risks of teratogenicity.  
Other routine risk minimisation measures beyond the product 
information: 
- Routine signal management  
- PSUR 
Psychiatric Disorders- 
including depression, 
suicidality and anxiety 
Routine risk communication: 
Provide in SmPC section 4.4 Special warnings and precautions 
for use 
Psychiatric disorders 
Psychiatric disorders Depression, depression aggravated, anxiety, 
aggressive tendencies, mood alterations, psychotic symptoms and, 
very rarely, suicidal ideation, suicide attempts and suicide have been 
reported in patients treated with isotretinoin (see section 4.8). 
Particular care needs to be taken in patients with a history of 
depression and all patients should be monitored for signs of 
depression and referred for appropriate treatment if necessary. 
However, discontinuation of isotretinoin may be insufficient to 
alleviate symptoms and therefore further psychiatric or psychological 
evaluation may be necessary. 
Provide in SmPC section 4.8 Undesirable effects  
Rare (≥1/10,000 to <1/1,000): 
Depression, depression aggravated, aggressive tendencies, anxiety, 
mood alterations. 
Very rare (≤1/10,000): 
Abnormal behaviour, psychotic disorder, suicidal ideation, suicide 
attempt, suicide 
Associated wording is included in the PIL. 
Other routine risk minimisation measures beyond the product 
information: 
- Routine signal management  
- PSUR 
Severe increase in 
triglyceride levels, 
Routine risk communication: 
Provide in SmPC section 4.4 Special warnings and precautions 
for use 
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sometimes associated 
with acute pancreatitis 
Lipid metabolism  
Serum lipids (fasting values) should be checked before treatment, 1 
month after the start of treatment, and subsequently at 3 monthly 
intervals unless more frequent monitoring is clinically indicated. 
Elevated serum lipid values usually return to normal on reduction of 
the dose or discontinuation of treatment and may also respond to 
dietary measures.  
Isotretinoin has been associated with an increase in plasma 
triglyceride levels. Isotretinoin should be discontinued if 
hypertriglyceridaemia cannot be controlled at an acceptable level or 
if symptoms of pancreatitis occur (see section 4.8). Levels in excess 
of 800 mg/dL or 9 mmol/L are sometimes associated with acute 
pancreatitis, which may be fatal. 
Provide in SmPC section 4.8 Undesirable effects 
Very common (≥1/10) 
Blood triglycerides increased, high density lipoprotein decreased 
very rare (≤1/10,000) 
Hepatitis 
Associated wording is included in the PIL. 
Other routine risk minimisation measures beyond the product 
information: 
- Routine signal management  
- PSUR 
Severe allergic 
reactions 
Routine risk communication: 
Provide in SmPC section 4.4 Special warnings and precautions 
for use 
Allergic reactions  
Anaphylactic reactions have been rarely reported, in some cases 
after previous topical exposure to retinoids. Allergic cutaneous 
reactions are reported infrequently. Serious cases of allergic 
vasculitis, often with purpura (bruises and red patches) of the 
extremities and extracutaneous involvement have been reported. 
Severe allergic reactions necessitate interruption of therapy and 
careful monitoring. 
Provide in SmPC section 4.8 Undesirable effects 
Rare (≥1/10,000 to <1/1,000) 
Allergic skin reaction, anaphylactic reactions, hypersensitivity 
Associated wording is included in the PIL. 
Other routine risk minimisation measures beyond the product 
information: 
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- Routine signal management  
- PSUR 
Eye disorders 
including corneal 
opacities, reduced 
night vision and 
keratitis 
Routine risk communication: 
Provide in SmPC section 4.4 Special warnings and precautions for 
use 
Eye disorders  
Dry eyes, corneal opacities, decreased night vision and keratitis 
usually resolve after discontinuation of therapy. Dry eyes can be 
helped by the application of a lubricating eye ointment or by the 
application of tear replacement therapy. Intolerance to contact lenses 
may occur which may necessitate the patient to wear glasses during 
treatment. 
Decreased night vision has also been reported and the onset in some 
patients was sudden (see section 4.7). Patients experiencing visual 
difficulties should be referred for an expert ophthalmological opinion. 
Withdrawal of isotretinoin may be necessary. 
Provide in SmPC section 4.7 Effects on ability to drive and use 
machines 
A number of cases of decreased night vision have occurred during 
isotretinoin therapy and in rare instances have persisted after therapy 
(see sections 4.4 and 4.8). Because the onset in some patients was 
sudden, patients should be advised of this potential problem and 
warned to be cautious when driving or operating machines.  
Drowsiness, dizziness and visual disturbances have been reported 
very rarely. Patients should be warned that if they experience these 
effects, they should not drive, operate machinery or take part in any 
other activities where the symptoms could put either themselves or 
others at risk 
Provide in SmPC section 4.8 Undesirable effects 
Very common (≥1/10) 
Blepharitis, conjunctivitis, dry eye, eye irritation 
Very rare (<1/10,000) 
Blurred vision, cataract, colour blindness (colour vision deficiencies), 
contact lens intolerance, corneal opacity, decreased night vision, 
keratitis, papilloedema (as sign of benign intracranial hypertension), 
photophobia, visual disturbances 
Associated wording is included in the PIL. 
Other routine risk minimisation measures beyond the product 
information: 
- Routine signal management  
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- PSUR 
Musculoskeletal and 
connective tissue 
disorders including 
bone changes and 
rhabdomyolysis 
 
Routine risk communication: 
Provide in SmPC section 4.4 Special warnings and precautions 
for use 
Musculo-skeletal and connective tissue disorders  
Myalgia, arthralgia and increased serum creatine phosphokinase 
values have been reported in patients receiving isotretinoin, 
particularly in those undertaking vigorous physical activity (see 
section 4.8). Bone changes including premature epiphyseal closure, 
hyperostosis, and calcification of tendons and ligaments have 
occurred after several years of administration at very high doses for 
treating disorders of keratinisation. The dose levels, duration of 
treatment and total cumulative dose in these patients generally far 
exceeded those recommended for the treatment of acne. 
Provide in SmPC section 4.8 Undesirable effects 
Very common (≥1/10) 
Athralgia, myalgia, back pain (particularly adolescent patients)  
Very rare (<1/10,000) 
Arthritis, calcinosis (calcification of ligaments and tendons), 
epiphyses premature fusion, exostosis, (hyperostosis), reduced 
bone density, tendonitis 
Associated wording is included in the PIL. 
Other routine risk minimisation measures beyond the product 
information: 
- Routine signal management  
- PSUR 
Severe skin reactions 
(including SJS and 
TEN) 
Routine risk communication: 
Provide in SmPC section 4.4 Special warnings and precautions 
for use 
Skin and subcutaneous tissue disorders  
Acute exacerbation of acne is occasionally seen during the initial 
period but this subsides with continued treatment, usually within 7-10 
days, and usually does not require dose adjustment.  
Exposure to intense sunlight or to UV rays should be avoided. Where 
necessary a sunprotection product with a high protection factor of at 
least SPF 15 should be used.  
Aggressive chemical dermabrasion and cutaneous laser treatment 
should be avoided in patients on isotretinoin for a period of 5-6 
months after the end of the treatment because of the risk of 
hypertrophic scarring in atypical areas and more rarely post 
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inflammatory hyper or hypopigmentation in treated areas. Wax 
depilation should be avoided in patients on isotretinoin for at least a 
period of 6 months after treatment because of the risk of epidermal 
stripping.  
Concurrent administration of isotretinoin with topical keratolytic or 
exfoliative anti-acne agents should be avoided as local irritation may 
increase (see section 4.5).  
Patients should be advised to use a skin moisturising ointment or 
cream and a lip balm from the start of treatment as isotretinoin is likely 
to cause dryness of the skin and lips. 
There have been post-marketing reports of severe skin reactions 
(e.g. erythema multiforme (EM), Stevens-Johnson syndrome (SJS) 
and toxic epidermal necrolysis (TEN)) associated with isotretinoin 
use. As these events may be difficult to distinguish from other skin 
reactions that may occur (see section 4.8), patients should be 
advised of the signs and symptoms and monitored closely for severe 
skin reactions. If a severe skin reaction is suspected, isotretinoin 
treatment should be discontinued. 
Provide in SmPC section 4.5 Interaction with other medicinal 
products and other forms of interaction 
Concurrent administration of isotretinoin with topical keratolytic or 
exfoliative anti-acne agents should be avoided as local irritation may 
increase (see section 4.4). 
 
Provide in SmPC section 4.8 Undesirable effects 
Very Common (≥1/10) 
Cheilitis, Dermatitis, Dry skin, Localised exfoliation, Pruritus, Rash 
erythematous, Skin fragility (and risk of frictional trauma) 
Rare (≥1/10 000 to <1/1 000) 
Alopecia 
Very Rare (<1/10,000) 
Acne fulminans, Acne aggravated (acne flare), Erythema (facial), 
Exanthema, Hair disorders, Hirsutism, Nail dystrophy, Paronychia, 
Photosensitivity reaction, Pyogenic granuloma, Skin 
hyperpigmentation, Sweating increased 
Not Known (cannot be estimated from the available data) 
Erythema multiforme, Stevens-Johnson Syndrome, toxic epidermal 
necrolysis. 
Associated wording is included in the PIL. 
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Other routine risk minimisation measures beyond the product 
information: 
- Routine signal management  
- PSUR 
Benign intracranial 
hypertension 
 
Routine risk communication: 
Provide in SmPC section 4.4 Special warnings and precautions 
for use 
Benign intracranial hypertension Cases of benign intracranial 
hypertension have been reported, some of which involved 
concomitant use of tetracyclines (see sections 4.3 and 4.5). Signs 
and symptoms of benign intracranial hypertension include headache, 
nausea and vomiting, visual disturbances and papilloedema. Patients 
who develop benign intracranial hypertension should discontinue 
isotretinoin immediately. 
Provide in SmPC section 4.3 Interaction with other medicinal 
products and other forms of interaction 
Cases of benign intracranial hypertension (pseudotumour cerebri) 
have been reported with concomitant use of isotretinoin and 
tetracyclines. Therefore, concomitant treatment with tetracyclines 
must be avoided (see section 4.3 and section 4.4). 
Provide in SmPC section 4.8 Undesirable effects 
Very Rare (<1/10,000) 
Benign intracranial hypertension Convulsions, Drowsiness, 
Dizziness 
Associated wording is included in the PIL. 
Other routine risk minimisation measures beyond the product 
information: 
- Routine signal management  
- PSUR 
Gastrointestinal 
disorders including 
inflammatory bowel 
disease 
Routine risk communication: 
Provide in SmPC section 4.4 Special warnings and precautions 
for use 
Gastrointestinal disorders  
Isotretinoin has been associated with inflammatory bowel disease 
(including regional ileitis) in patients without a prior history of intestinal 
disorders. Patients experiencing severe (haemorrhagic) diarrhoea 
should discontinue isotretinoin immediately. 
Provide in SmPC section 4.8 Undesirable effects 
Very Rare (<1/10,000) 
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Colitis, Ileitis, Dry throat, Gastrointestinal haemorrhage, 
haemorrhagic diarrhoea and inflammatory bowel disease, Nausea 
Associated wording is included in the PIL. 
Other routine risk minimisation measures beyond the product 
information: 
- Routine signal management  
- PSUR 
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V.2. Additional Risk Minimisation Measures  
 
Teratogenicity and drug exposure during pregnancy 
 
Healthcare Professional and Patient/Carer Guide  
The term guide can refer to any descriptive material that educates Healthcare 
Professional and/or patients/caregivers about specific risks, and/or their early symptoms, 
and/or the best course of action to be taken when these appear beyond the 
recommendation contained in the Product Information. A guide may also aim to raise 
awareness about an on-going (imposed) registry/study, as well as about the general 
value of reporting adverse events. Terms such as ‘brochure’, ‘leaflet’ should be avoided 
and the term ‘guide’ should be used instead. 
 
Pregnancy prevention programmes 
A pregnancy prevention programme (PPP) is a set of interventions aiming to minimise 
pregnancy exposure during treatment with a medicinal product with known or potential 
teratogenic effects. The scope of such a programme is to ensure that female patients 
are not pregnant when starting therapy or do not become pregnant during the course 
and/or soon after stopping the therapy. It could also target male patients when use of a 
medicinal product by the biological father might have a negative effect on the pregnancy 
outcome. A PPP combines the use of educational tools with interventions to control 
appropriately access to the medicine. Therefore, the following elements should be 
considered individually and/or in combination in the development of a PPP.  
• Educational tools targeting healthcare professionals and patients to inform on the 
teratogenic risk and required actions to minimise this risk e.g. guidance on the need to 
use more than one method of contraception and guidance on different types of 
contraceptives; information included for the patient on how long to avoid pregnancy after 
treatment is stopped; information for when the male partner is treated;  
• Controlled access at prescribing or dispensing level to ensure that a pregnancy test is 
carried out and negative results are verified by the healthcare professional before 
prescription or dispensing of the medicinal product; 
• Prescription limited to a maximum of 30 days’ supply;   
• Counselling in the event of inadvertent pregnancy and evaluation of the outcome of any 
accidental pregnancy.  
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Prescriber checklist 
Used to facilitate patient selection when initiating therapy or repeat prescription is issued, 
as appropriate. The checklist should remind prescribers of e.g. a restricted indication, 
contraindications, warnings and precautions needed for the use of a medicinal product 
particularly relating to important safety concerns in the SmPC and to facilitate the need 
for examination of specific aspects of the patient’s health before initiating treatment 
and/or during continuous monitoring as appropriate. 
 
Objectives:  
In order to assist prescribers, pharmacists and patients in avoiding foetal exposure to 
isotretinoin, the Stala Pharma provide educational materials to reinforce the warnings 
about the teratogenicity of isotretinoin, to provide advice on contraception before therapy 
is started and to provide guidance on the need for pregnancy testing. 
Full patient information about the teratogenic risk and the strict pregnancy prevention 
measures as specified in the Pregnancy Prevention Programme should be given by the 
physician to all patients, both male and female. 
 
Rationale for the additional risk minimisation activity: 
The PPP is need to avoid foetal exposure to isotretinoin. Isotretinoin is a powerful human 
teratogen inducing a high frequency of severe and life-threatening birth defects. 
 
Target audience and planned distribution path: 
Educational materials for prescribers, pharmacists and patients are distributed via 
pharmaceutical representatives. 
Educational materials for patients are distributed by prescribers. 
 
To the prescriber: 
- Physician Checklist/Acknowledgement Form for prescribing to Female Patients 
aiming to inform the doctors about the risks and prevention of teratogenicity. 
 
To the pharmacist: 
- Pharmacist checklist to isotretinoin dispensing aiming to inform the pharmacist 
about the risks and prevention of teratogenicity.  
 
To the patients: 
- Patient Information Sheet; 
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- Patient reminder card (including appointment table). 
 
Plans to evaluate the effectiveness of the interventions and criteria for success: 
 
How effectiveness of risk minimisation measures for the safety concern will be measured 
by monitoring the reporting rate of the reported cases. 
Criteria for judging the success of the proposed risk minimisation measures: 
- If no new safety data emerge providing evidence of increased frequency of 
Teratogenicity and drug exposure during pregnancy related ADRs. 
- Planned dates for assessment periodically in the context of signal detection and in each 
PSUR/ PBRER. 
- Results of effectiveness measurement Assessment in each update of RMP. 
- Impact of risk minimisation: Labelling and packaging could be updated in accordance 
with new information which could lead to reinforcement of the current risk and direct 
healthcare professional communication (DHCP). 
 
Neuropsychiatric effects 
 
Healthcare Professional and Patient/Carer Guide  
The term guide can refer to any descriptive material that educates Healthcare 
Professional and/or patients/caregivers about specific risks, and/or their early symptoms, 
and/or the best course of action to be taken when these appear beyond the 
recommendation contained in the Product Information. A guide may also aim to raise 
awareness about an on-going (imposed) registry/study, as well as about the general 
value of reporting adverse events. Terms such as ‘brochure’, ‘leaflet’ should be avoided 
and the term ‘guide’ should be used instead. 
 
Objectives:  
Particular care needs to be taken in patients with history of depression and all patients 
should be monitored for signs of depression or suicidal ideation.  
 
Rationale for the additional risk minimisation activity: 
The risk minimisation measures are being developed to ensure that healthcare 
professionals (HCPs) and patients are informed about the risks associated with oral 
retinoids before starting the treatment, and that adequate counselling regarding the risks 
is given. 
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Target audience and planned distribution path: 
Educational materials for prescribers and patients are distributed via pharmaceutical 
representatives to prescribers and to the pharmacies they visit. 
Educational materials for patients are distributed by prescribers. 
 
To the prescriber 
Doctor’s guide for isotretinoin prescription aiming to inform the prescribers about the risks 
and prevention of psychiatric disorders. 
 
To the pharmacist 
Pharmacist guide to isotretinoin dispensing aiming to inform the pharmacist about the 
risks and prevention of psychiatric disorders. 
A mention was added to reinforce the warning: 
“in case your patient mentions to your symptoms that could be evocative of depressive 
disorders, do not hesitate to refer your patient to the prescriber” 
 
To the patient 
The guide aims to inform patients about the risks and prevention of psychiatric disorders. 
 
Plans to evaluate the effectiveness of the interventions and criteria for success: 
How effectiveness of risk minimisation measures for the safety concern will be measured 
by monitoring the reporting rate of the reported cases. 
Criteria for judging the success of the proposed risk minimisation measures: 
- If no new safety data emerge providing evidence of increased frequency of 
Teratogenicity and drug exposure during pregnancy related ADRs. 
- Planned dates for assessment periodically in the context of signal detection and in each 
PSUR/ PBRER 
- Results of effectiveness measurement Assessment in each update of RMP 
- Impact of risk minimisation: Labelling and packaging could be updated in accordance 
with new information which could lead to reinforcement of the current risk and Dear 
healthcare professional communication (DHPC). 
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Severe lipid metabolism disorders with acute pancreatitis 
 
Healthcare Professional and Patient/Carer Guide  
The term guide can refer to any descriptive material that educates Healthcare 
Professional and/or patients/caregivers about specific risks, and/or their early symptoms, 
and/or the best course of action to be taken when these appear beyond the 
recommendation contained in the Product Information. A guide may also aim to raise 
awareness about an on-going (imposed) registry/study, as well as about the general 
value of reporting adverse events. Terms such as ‘brochure’, ‘leaflet’ should be avoided 
and the term ‘guide’ should be used instead. 
 
Objectives:  
The goal of this additional measure is to be aware of the risks associated with 
hypertriglyceridemia levels in excess which is sometimes associated with acute 
pancreatitis. Consequently, can be fatal. 
 
Rationale for the additional risk minimisation activity: 
The risk minimisation measures are being developed to ensure that healthcare 
professionals (HCPs) and patients are informed about the risks associated with oral 
retinoids and that adequate counselling regarding the risks is given. 
 
Target audience and planned distribution path: 
Educational materials for prescribers and patients are distributed via pharmaceutical 
representatives to prescribers and to the pharmacies they visit. 
Educational materials for patients are distributed by prescribers. 
 
To the prescriber, pharmacist and patient 
Guides aim to inform about the risks of severe lipid metabolism disorders with acute 
pancreatitis and special biologic surveillance: 
Serum lipids (fasting values) should be checked before treatment, 1 month after the start 
of treatment, and subsequently at 3 monthly intervals unless more frequent monitoring 
is clinically indicated. 
 
Plans to evaluate the effectiveness of the interventions and criteria for success: 
How effectiveness of risk minimisation measures for the safety concern will be measured 
by monitoring the reporting rate of the reported cases. 
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Criteria for judging the success of the proposed risk minimisation measures: 
- If no new safety data emerge providing evidence of increased frequency of 
Teratogenicity and drug exposure during pregnancy related ADRs. 
- Planned dates for assessment periodically in the context of signal detection and in each 
PSUR/ PBRER 
- Results of effectiveness measurement Assessment in each update of RMP 
- Impact of risk minimisation: Labelling and packaging could be updated in accordance 
with new information which could lead to reinforcement of the current risk and Dear 
healthcare professional communication (DHPC). 
 
V.3 Summary of risk minimisation measures   
 
Table 40 - Part V.3: Summary table of PhV activities and RMM by safety concern 
Safety concern Risk minimisation measures Pharmacovigilance 
activities 
Teratogenicity Routine risk minimisation 
measures: 
SmPC section 4.3 where is 
contraindicated the use of 
isotretinoin in women who are 
pregnant or breastfeeding.  
SmPC section 4.4 where special 
warnings and precautions for use of 
isotretinoin is mentioned.    
SmPC section 4.6 
Associated wording is included in 
the PL section 2. 
Labelling also warning about the 
risks of teratogenicity.  
Additional risk minimisation 
measures: 
- Physician Checklist/ 
Acknowledgement Form for 
Prescribing to Female Patients 
- Pharmacist checklist 
- Patient Information Sheet 
- Patient Reminder Card 
Routine pharmacovigilance 
activities beyond adverse 
reactions reporting and signal 
detection: 
- AE follow-up form for 
adverse reaction 
- PSUR 
Additional pharmacovigilance 
activities:  
Post-Authorisation Safety 
Study (PASS) to evaluate de 
effectiveness of the 
implementation of these risk 
minimisation measures 
(RMMs). 
 
Psychiatric 
Disorders- including 
Routine risk minimisation 
measures: 
Routine pharmacovigilance 
activities beyond adverse 
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Safety concern Risk minimisation measures Pharmacovigilance 
activities 
depression, 
suicidality and 
anxiety 
SmPC section 4.4 Special 
warnings and precautions for use 
in Psychiatric disorders 
SmPC section 4.8 
Associated wording is included in 
the PL section 2 and 4. 
Additional risk minimisation 
measures: 
- Healthcare Professional 
Guide 
- Patient guide 
reactions reporting and signal 
detection: 
- AE follow-up form for 
adverse reaction 
- PSUR 
Additional pharmacovigilance 
activities:  
Post-Authorisation Safety 
Study (PASS) to evaluate de 
effectiveness of the 
implementation of these risk 
minimisation measures 
(RMMs). 
Severe increase in 
triglyceride levels, 
sometimes 
associated with acute 
pancreatitis 
Routine risk minimisation 
measures: 
SmPC section 4.4 where advice is 
given on monitoring the lipid levels. 
SmPC section 4.8 
Associated wording is included in 
the PL section 2 and 4. 
Additional risk minimisation 
measures: 
- Healthcare Professional 
Guide 
- Patient guide 
Routine pharmacovigilance 
activities beyond adverse 
reactions reporting and signal 
detection: 
- AE follow-up form for 
adverse reaction 
- PSUR 
Additional pharmacovigilance 
activities:  
Post-Authorisation Safety 
Study (PASS) to evaluate de 
effectiveness of the 
implementation of these risk 
minimisation measures 
(RMMs). 
Severe skin reactions Routine risk minimisation 
measures: 
SmPC section 4.4 Special 
warnings and precautions for use.  
SmPC section 4.8 
Associated wording is included in 
the PL section 2 and 4. 
Routine pharmacovigilance 
activities beyond adverse 
reactions reporting and signal 
detection: 
- AE follow-up form for 
adverse reaction 
- PSUR 
 
Eye disorders 
including corneal 
Routine risk minimisation 
measures: 
Routine pharmacovigilance 
activities beyond adverse 
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Safety concern Risk minimisation measures Pharmacovigilance 
activities 
opacities, reduced 
night vision and 
keratitis 
 
SmPC section 4.4 where advice is 
given relating to the eye discords. 
SmPC section 4.7 where advice is 
given on the ability to drive and use 
machines. 
SmPC section 4.8 
Associated wording is included in 
the PL section 2 and 4. 
 
reactions reporting and signal 
detection: 
- AE follow-up form for 
adverse reaction 
- PSUR 
 
Musculoskeletal and 
connective tissue 
disorders including 
bone changes and 
rhabdomyolysis 
 
Routine risk minimisation 
measures: 
SmPC section 4.4 Special 
warnings and precautions for use.  
SmPC section 4.8 
Associated wording is included in 
the PIL PL section 2 and 4. 
 
Routine pharmacovigilance 
activities beyond adverse 
reactions reporting and signal 
detection: 
- AE follow-up form for 
adverse reaction 
- PSUR 
 
Severe skin reactions 
(including SJS and 
TEN) 
Routine risk minimisation 
measures: 
SmPC section 4.4 Special 
warnings and precautions for use.  
SmPC section 4.5 and 4.8 
Associated wording is included in 
the PL section 2 and 4. 
 
Routine pharmacovigilance 
activities beyond adverse 
reactions reporting and signal 
detection: 
- AE follow-up form for 
adverse reaction 
- PSUR 
 
Benign intracranial 
hypertension 
 
Routine risk minimisation 
measures: 
SmPC section 4.4 Special 
warnings and precautions for use.  
SmPC section 4.5 and 4.8 
Associated wording is included in 
the PL section 2 and 4. 
 
Routine pharmacovigilance 
activities beyond adverse 
reactions reporting and signal 
detection: 
- AE follow-up form for 
adverse reaction 
- PSUR 
 
Gastrointestinal 
disorders including 
inflammatory bowel 
disease 
Routine risk minimisation 
measures: 
SmPC section 4.4 Special 
warnings and precautions for use.  
SmPC section 4.8 
Routine pharmacovigilance 
activities beyond adverse 
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Safety concern Risk minimisation measures Pharmacovigilance 
activities 
Associated wording is included in 
the PL section 2 and 4. 
reactions reporting and signal 
detection: 
- AE follow-up form for 
adverse reaction 
- PSUR 
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Part VI: Summary of the risk management plan     
 
Summary of risk management plan for Isotretinoin generics (Isotretinoin) 
 
This is a summary of the risk management plan (RMP) for isotretinoin generics. The 
RMP details important risks of isotretinoin generics, how these risks can be minimised, 
and how more information will be obtained about isotretinoin generics’ risks and 
uncertainties (missing information). 
 
Isotretinoin generics’ summary of product characteristics (SmPC) and its package leaflet 
give essential information to healthcare professionals and patients on how isotretinoin 
generics should be used.  
 
I. The medicine and what it is used for 
 
Isotretinoin generics is authorised for severe forms of acne (such as nodular and 
conglobate acne or acne at risk of permanent scarring) resistant to adequate courses of 
standard therapy with systemic antibacterial and topical therapy (see SmPC for the full 
indication). It contains isotretinoin as the active substance and it is given by oral use by 
soft capsules with 10 mg of isotretinoin. 
 
II. Risks associated with the medicine and activities to minimise or 
further characterise the risks  
 
Important risks of Isotretinoin generics, together with measures to minimise such risks 
and the proposed study for learning more about Isotretinoin generics' risks, are outlined 
below. 
Measures to minimise the risks identified for medicinal products can be: 
Specific information, such as warnings, precautions, and advice on correct use, in the 
package leaflet and SmPC addressed to patients and healthcare professionals; 
Important advice on the medicine’s packaging; 
 
The authorised pack size — the amount of medicine in a pack is chosen so to ensure 
that the medicine is used correctly; 
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The medicine’s legal status — the way a medicine is supplied to the patient (e.g. with or 
without prescription) can help to minimise its risks. 
Together, these measures constitute routine risk minimisation measures. 
 
In the case of Isotretinoin generics, these measures are supplemented with additional 
risk minimisation measures mentioned under relevant important risks, below. 
 
In addition to these measures, information about adverse reactions is collected 
continuously and regularly analysed, including PSUR assessment - so that immediate 
action can be taken as necessary. These measures constitute routine 
pharmacovigilance activities.  
 
II.A List of important risks and missing information 
 
Important risks of Isotretinoin are risks that need special risk management activities to 
further investigate or minimise the risk, so that the medicinal product can be safely taken. 
Important risks can be regarded as identified or potential. Identified risks are concerns 
for which there is sufficient proof of a link with the use of Isotretinoin generics. Potential 
risks are concerns for which an association with the use of this medicine is possible 
based on available data, but this association has not been established yet and needs 
further evaluation. Missing information refers to information on the safety of the medicinal 
product that is currently missing and needs to be collected (e.g. on the long-term use of 
the medicine); 
 
Table 41 – List of important risks and missing information 
List of important risks and missing information  
Important identified risks Teratogenicity 
Psychiatric Disorders- including depression, suicidality and 
anxiety 
Eye disorders including corneal opacities, reduced night 
vision and keratitis 
Musculoskeletal and connective tissue disorders including 
bone changes and rhabdomyolysis 
Severe skin reactions (including SJS and TEN) 
Benign intracranial hypertension 
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List of important risks and missing information  
Severe increase in triglyceride levels, sometimes associated 
with acute pancreatitis 
Severe allergic reactions 
Important potential risks Gastrointestinal disorders including inflammatory bowel 
disease 
Missing information Not applicable 
 
II.B Summary of important risks 
 
Table 42 – Summary of important risks 
Important identified risk  
Teratogenicity 
Risk minimisation measures 
 
Routine risk minimisation measures 
- AE follow-up form for adverse reaction 
- PSUR 
Additional risk minimisation measures 
- Physician Checklist/Acknowledgement Form for 
Prescribing to Female Patients; 
- Pharmacist Checklist; 
- Patient Information Sheet; 
- Patient Alert Card (including appointment table). 
Psychiatric Disorders- including depression, suicidality and anxiety 
Risk minimisation measures 
 
Routine risk minimisation measures 
- AE follow-up form for adverse reaction 
- PSUR 
Additional risk minimisation measures 
- Healthcare Professional Guide 
     -     Patient guide 
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Important identified risk  
Severe increase in triglyceride levels, sometimes associated with acute 
pancreatitis 
Risk minimisation 
measures 
 
Routine risk minimisation measures 
- AE follow-up form for adverse reaction 
- PSUR 
Additional risk minimisation measures 
- Healthcare Professional Guide 
     -     Patient guide 
 
II.C Post-authorisation development plan 
 
II.C.1 Studies which are conditions of the marketing authorisation 
There are no studies which are conditions of the marketing authorisation or specific 
obligation of Isotretinoin Generics. 
 
II.C.2 Other studies in post-authorisation development plan 
There are no studies required for Isotretinoin Generics. 
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Part VII: Annexes 
 
Annex 1 – EudraVigilance Interface 
 
Annex 2 – Tabulated summary of planned, ongoing, and completed  
 
Pharmacovigilance study programme  
 
Table 43 - Annex II: Planned and on-going studies 
Study 
Summary of 
objectives 
Safety concerns 
addressed 
Protocol link 
Milestones 
LE observational 
cohort safety 
study  
(study LE123) 
 
Category 3 
To evaluate the 
effectiveness of 
the 
implementation 
of the risk 
minimisation 
measures 
Teratogenicity 
 
Psychiatric 
Disorders- including 
depression, 
suicidality and 
anxiety 
 
Severe increase in 
triglyceride levels, 
sometimes 
associated with 
acute pancreatitis 
Interim results: Not 
applicable 
Final study report 
submission: 9 
September 2018 
 
Annex 3 - Protocols for proposed, on-going and completed studies in the 
pharmacovigilance plan  
The study above is not imposed and not required for this reason the protocol is not 
included.  
 
Annex 4 - Specific adverse drug reaction follow-up forms 
Table of contents 
Follow-up forms 
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ADVERSE DRUG REACTION FOLLOW-UP FORM 
 
 
File number: |__|__| - |__|__|__|__| - |__|__|__|__| 
 
PATIENT IDENTIFICATION 
Last name (First 3 letters) : |__|__|__|  Sex : F □ M □ 
First name (First 2 letters) : |__|__|  
 
 
SUSPECTED DRUG INVOLVED: 
Trade Name: _____________ Dosage: _____________ 
Indication (specify the severity):__________________________________________ 
Date of onset of reaction: ___/___/___ Time to onset of reaction: ___/___/___  
 
DESCRIPTION OF THE ADVERSE(S) REACTION(S) 
__________________________________________________________________________
__________________________________________________________________________
________________ 
 
FOLLOW-UP 
RESULTS OF ANY ADDITIONAL EXAMINATIONS ordered following the side effect 
(Attach photocopies if possible) 
 
 
 
 
 
 
Signature________________________ Date___/___/___ 
 
 
 
 
 
 
Signature________________________ Date___/___/___ 
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Signature________________________ Date___/___/___ 
 
 
 
 
 
 
 
Signature________________________ Date___/___/___ 
 
 
 
 
 
 
 
 
CLOSED CASE TO FOLLOW-UP 
 
 
Case without further information to receive: 
Results with known final                     □ 
 
Assessment made by the notifier            □ 
 
Knowledge of the important data            □ 
required for the case assessment              
 
Impossibility of following-up 
Non collaboration with the notifier      □ 
 
Loss of contact with the notifier          □ 
 
Loss of contact between the  
notifier and the patient                        □ 
 
 
Signature________________________   Date___/___/___ 
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Annex 5 - Protocols for proposed and on-going studies in RMP part IV 
This section is not applicable 
 
Annex 6 - Details of proposed additional risk minimisation activities  
 
Draft key messages of the additional risk minimisation measures 
  
Physician educational material: 
 The Summary of Product Characteristics 
 Guide for healthcare professionals: 
o Relevant information of the safety concern(s) addressed by the aRMM (e.g. 
seriousness, severity, frequency, time to onset, reversibility of the AE as 
applicable); 
o Details of the population at higher risk for the safety concern addressed by 
the aRMM (e.g. contraindications, risk factors, increased risk by interactions 
with certain medicine); 
o Details on how to minimise the safety concern addressed by the aRMM 
through appropriate monitoring and management (e.g. what to do, what not 
do, and who is most likely to be impacted according to different scenarios, 
like when to limit or stop prescribing/ingestion, how to administer the 
medicine, when to increase/decrease the dosage according to laboratory 
measurements, signs and symptoms); 
o Key message to convey in patients counselling;  
o Instructions on how to handle possible adverse events. 
 Prescriber checklist: 
o Lists of tests to be conducted for the initial screening of the patient; 
o Premedication, general health, and pregnancy and contraception checks 
immediately before/during/after treatment; 
o A specific reference to the fact that the patient has been informed and 
understands the potential teratogenic risks of foetal malformations and the 
measures to minimise them. 
 
The patient information pack: 
o Patient information leaflet 
 Patient/carer guide: 
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o A description of the potential teratogenic risks(s) associated with the use of 
Isotretinoin Generics namely: foetal malformations.  
o A description of the correct use of Isotretinoin Generics and the potential risks 
associated with its use, namely: foetal malformations, psychiatric disorders – 
including depression, suicidality and anxiety and severe increase in 
triglyceride levels, sometimes associated with acute pancreatitis. 
o Recommendations for the planning of the monitoring schedule 
For pregnancy-related risks: 
o Recommendation not to take Isotretinoin Generics in case of pregnancy 
o For women of child bearing potential recommendation to use effective 
contraception methods 
o Recommendation for regular pregnancy testing 
 
Annex 7 - Other supporting data (including referenced material) 
Isotretinoin Generics 10/0000/m1/eu/13-pi/13.1-pil/Portugal 
Isotretinoin Generics 10/0000/m1/eu/13-pi/13.1-SmPC/Portugal 
Isotretinoin Generics 10/0000/m1/eu/13-pi/13.1-Labelling/Portugal 
 
Annex 8 – Summary of changes to the risk management plan over time 
This is the first version of RMP of the medicinal product Isotretinoin Generics so the list 
of all significant changes to the Risk Management Plan over time is not applicable. 
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Risk Minimization Measures of 
Isotretinoin Generics 
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Retinoids are natural or synthetic vitamin A derivatives with pleiotropic effects that 
regulate cell differentiation, proliferation and apoptosis. First-generation retinoids include 
retinol tretinoin (all-trans-retinoic acid) isotretinoin (13-cis-retinoic acid) and alitretinoin 
(9-cis-retinoic acid). Second-generation retinoids also known as aromatic retinoids were 
created by alteration of the cyclic end group and include acitretin. Third-generation 
retinoids contain further modifications and are called arotinoids. Members of this 
generation include tazarotene and bexarotene. Adapalene a derivative of naphthoic acid 
with retinoid-like properties does not fit precisely into any of the three generations (42). 
In general, dietary surveys have revealed that the average un-supplemented adult diet 
contains 7000 IU to 8000 lU/day of vitamin A (45). 
 
The activity of retinoids is mediated by Nuclear Retinoid Receptors (RNR) belonging to 
the superfamily of receptors activated by steroids, thyroid hormone, vitamin D and 
peroxisome proliferation. Vitamin A is essential to human health and naturally occurring 
in the blood however concerns have arisen regarding its potential teratogenicity [42]. 
 
Whether excessive vitamin A intake possibly causes birth defects not only in animals but 
also in man represents a still unresolved public health concern (46). Due to the low 
incidence of possibly vitamin A-related malformations in man available data cannot 
convincingly define the upper safe limit of periconceptional vitamin A intake. One study 
suggests the possible teratogenic effects of high doses of vitamin A (40000 IU and more) 
when women were exposed to it during the organogenetic period (the first two months) 
(47). Human intervention studies are not feasible for ethical reasons.  
 
Retinoid-containing medicinal products are available in oral and topical forms and are 
authorised both centrally and nationally. They are widely used to treat a variety of 
conditions mainly affecting the skin such as various forms of acne, severe chronic hand 
eczema unresponsive to corticosteroids, severe forms of psoriasis and keratinisation 
disorders (45). 
 
Retinoids are recognised to be teratogenic at the recommended therapeutic dose of the 
oral formulations. The main known teratogenic effects are central nervous system, 
craniofacial, cardiovascular and thyme abnormalities (45).  
 
Pregnancy is an absolute contraindication in the SmPCs for all oral retinoids in the EU. 
A referral in 2003 for isotretinoin led to introduction of the isotretinoin pregnancy 
prevention programme (PPP) in the EU. Since the introduction of the PPP for isotretinoin 
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similar programmes have been introduced for the other oral retinoids used to treat 
dermatological conditions. The effectiveness of these PPPs has been kept under close 
review and although a reduction in the number of pregnancies exposed to these retinoids 
has been observed cases of pregnancies exposed to retinoids continue to occur (42)  
 
In 2016, the PRAC reviewed the effectiveness of the PPP for oral isotretinoin and noted 
post-marketing data and published studies raising concerns about how well the 
requirements of the PPP are followed in clinical practice. These data suggested that 
there were a large area that may impact on the effectiveness of the PPP including 
inconsistencies in information provided with regard to contraceptive measures and a lack 
of up-to-date information about the most effective contraceptive methods inadequate 
documentation of the required patient monitoring and potential differences in the 
pregnancy prevention programmes implemented across the generics. Consequently, the 
PRAC identified a need for a detailed assessment of compliance with the requirements 
of the PPP for isotretinoin (42). 
 
In conclusion, PRAC considered there is a need to thoroughly review the routine risk 
minimisation (warnings in the SmPC and package leaflet) in place for the oral and topical 
retinoids to ensure the available data and the risks associated with the adverse 
teratogenic effects are accurately and consistently addressed within the product 
information where appropriate and justified by data. Furthermore, it is necessary to 
review any additional risk minimisation measures to ensure that these are optimal in 
terms of provision of information and delivery of effective risk management that is subject 
to appropriate monitoring (42). 
 
Therefore, on 7 July 2016 the UK Medicines and Healthcare Products Regulatory 
Agency (MHRA) triggered a referral under Article 31 of Directive 2001/83/EC and asked 
the PRAC to assess the impact of the above concerns on the benefit-risk balance of 
retinoid-containing medicinal products and issue a recommendation on whether the 
products should be maintained, varied, suspended or revoked (42). 
 
As a result, in February 2018 the PRAC concluded its review of retinoid medicines and 
recommended updating the measures for pregnancy prevention and including a warning 
on the possible risk of neuropsychiatric disorders (such as depression, anxiety and mood 
changes) (42). 
In March 2018 the European Medicines Agency has completed its review of retinoid 
medicines and confirmed that an update of actions for pregnancy prevention was 
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needed. In addition, a warning on the possibility that neuropsychiatric disorders (such as 
depression, anxiety and mood changes) may occur would be included in the prescribing 
information for oral retinoids (42). 
 
The steps of the referral process, taken from the website of EMA, for the retinoids and 
the final outcome are presented as following: 
 
Figure 2: Steps during the referral process of isotretinoin  
 
 
The CHMP opinion or the CMDh position by majority vote, was sent to the European 
Commission (EC), which took a final decision valid across the EU. (19,36) 
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Figure 3: The overall process including timelines for adoption of an opinion, position, or agreement. 
 
Afterwards the EC  initiated the decision-making process which led  to the adoption of a 
binding decision addressed either to the MAHs or MSs, depending on whether the 
decision concerns centrally authorised products (CAPs) or nationally authorised 
products (including via the mutual recognition and decentralised procedures), 
respectively (19, 36) 
 
Adequacy of existing PPP and proposals for any updates 
 
It is the nature of the contraception (e.g. user independent forms such as implants or 
intrauterine devices) that is more likely to increase the effectiveness rather than the 
number of different forms used. With regards to pregnancy testing, the existing PPPs 
requires monthly pregnancy testing and the only exception is where the prescriber 
considers that there are compelling reasons to indicate that there is no risk of pregnancy 
and it seems important to retain this level of clinical discretion. It was noted there were 
several inconsistencies between the materials, not only between the different active 
substances but also between products with the same active substance (42, 43)  
 
Regarding the key messages, although some differences could be detected among the 
different products, it seems that the problem may not be regarding the content of the 
materials as the majority cover information on the teratogenic risks, conditions of 
prescribing, conditions for dispensing, information about the contraceptive methods, 
information for doctor, pharmacist and patient, including guides and acknowledgement 
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form. However, the current approved materials are very extensive and the information 
among the same set of materials is repetitive and these could be made more concise 
and focused (42, 43).  
 
It should also be highlighted that it would be important to reduce the number of different 
documents. Overly long and repetitive information does not enhance readability. 
Therefore, the materials should be made more concise and focused and this is true 
across all recipients – patients, physicians and pharmacists. 
 
The PPP should be updated, in accordance with core elements and principles defined in 
advance. The aim was to harmonize and simplify information for patients and HCPs. 
 
The following changes to the current educational materials are indicated in the following 
table: 
 
Table 44 - changes to the current educational materials 
 Previous educational 
materials 
Proposed educational 
materials 
Patient materials Patient brochure Patient information sheet 
Contraception advice 
brochure 
 
 Patient reminder card 
Physician materials Physician guide  
Physician checklist Physician 
checklist/acknowledgement 
form (merged document) 
Acknowledgement form 
Pharmacist materials Pharmacist brochure Pharmacist checklist 
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Figure 4: Illustration of the proposed educational materials 
 
 
Additionally, it is also considered necessary to improve not only the format and key 
messages of these materials, but also explore the possibility of electronic dissemination 
of these materials (e.g. website/URL, apps, SMS messaging), the feasibility of a patient 
reminder card inserted in outer packaging and also the possibility of using Quick 
Response code (QR code) on the outer packaging and package leaflet, among others 
(19, 43). 
 
The following core elements and principles should be implemented in each material: 
For all oral retinoids the key messages are: 
a. Teratogenicity risk – what it means to the unborn fetus 
b. Contraception – the ‘risk period’, and what measures need to be observed through 
this risk period 
c. Pregnancy testing – why this is important, and why monthly prescriptions are 
required  
 
For Isotretinoin Generics it is proposed to have now three educational materials, one for 
each of the patient, physician and pharmacist. Attached you can find the proposed 
educational materials. 
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Educational Materials for the patient, 
physician and pharmacist 
Isotretinoin Generics ® 
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1. Physician materials 
 
Physician Checklist /Acknowledgement Form for Prescribing to Female 
Patients 
 
The potential for pregnancy must be assessed for all female patients prescribed 
Isotretinoin Generics 
  
Is the patient a woman of childbearing potential? Yes No 
This checklist is to be completed by the Physician for all female patients prescribed 
Isotretinoin Generics and kept with patient notes to document compliance with the 
Isotretinoin Generics Pregnancy Prevention Programme. After completion a copy of this 
document should be given to the patient. 
Isotretinoin Generics belongs to the retinoid class of drugs that cause severe birth 
defects. Foetal exposure to Isotretinoin Generics, even for short periods, presents a high 
risk of congenital malformations. Retinoids are strictly contraindicated in women of 
childbearing potential, unless all conditions in the Isotretinoin Generics Pregnancy 
Prevention Programme are fulfilled. 
As the prescribing doctor, you must make sure that the risk of serious harm from drug 
exposed pregnancy is fully understood by all female patients before treating them with 
Isotretinoin Generics. 
Before initiating Isotretinoin Generics therapy in a female patient, the following checklist 
must be completed and stored in the patient’s notes. This checklist should also be used 
in all follow-up visits with women of childbearing potential.  
Please use the patient information sheet to support your discussion with the patient.  
 
 
 
 
 
 
 
A woman has a potential for pregnancy if one of the following applies: 
Is a sexually mature woman who: 
1) has not had a hysterectomy or bilateral oophorectomy 
2) is not in a natural postmenopause for a minimum of 24 consecutive months (ie, 
menstruated at a certain point in the last 24 consecutive months). 
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Women with childbearing potential 
 
Review the below statements, explain them to the patient and record confirmation of this 
and acknowledgment from the patient in this form. If the answer to any of these questions 
is NO, Isotretinoin Generics must not be prescribed. 
Table 45 – Doctor’s check list  
 Doctor confirm: 
I have explained 
this to my patient 
[YES/NO] 
Patient confirm: 
I have 
understood this 
[YES/NO] 
Teratogenicity 
 
The patient understands that 
Isotretinoin Generics belongs to a 
class of drugs (retinoids) known to 
cause severe birth defects and 
that they must not get pregnant 
whilst taking it. Isotretinoin 
Generics also increases the risk 
of miscarriage when taken during 
pregnancy 
 
  
Contraception 
 
The patient understands that she 
must consistently and correctly 
use at least 1 and preferably 2 
effective and complementary 
methods of birth control before 
and during treatment  
  
The patient understands that the 
risk persists even after the 
medication is stopped and that 
she must not get pregnant for 5 
weeks after stopping treatment  
  
The patient has received advice 
on contraception which is 
appropriate for them and has 
committed to using it throughout 
the risk period 
  
The patient is aware of the risk of 
contraceptive failure 
  
Pregnancy Testing & Monthly Prescriptions 
The first prescription for 
Isotretinoin Generics can only be 
given after the patient has had 
one negative medically 
supervised pregnancy test. This is 
to make sure she is not already 
pregnant before starting treatment 
  
Patient Understands that only a 
30 day supply can be given and 
the prescription must be used in 7 
days. 
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Patient understands the need for 
and agrees to pregnancy testing 
before, during and after treatment 
 
  
Patient understands the need to 
do a pregnancy test 5 weeks after 
stopping treatment because the 
drug stays in the body for 5 weeks 
after the last dose and can 
damage an unborn baby if 
pregnancy occurs. 
  
The contraceptive methods and 
pregnancy test results were 
recorded in the patient’s 
appointment table (included in 
patient reminder card) 
  
The patient has received a copy 
of the educational package  
  
The patient knows to contact their 
doctor if they have unprotected 
sex, miss their 
period, become pregnant, or 
suspect that they have become 
pregnant during the risk period 
  
If pregnancy occurs, treatment 
must be stopped and the patient 
should be referred to an expert 
physician specialised or 
experienced in teratology for 
advice. 
  
Signature   
Date   
 
The pregnancy should be reported to the MAH Stala Pharma G though the address 
below, who will follow up with you to record the pregnancy outcome. 
 
Contact details: 
Stala Pharma G 
QPPV: Patrícia de Lurdes Douteiro Rodrigues 
Telephone: +351211122333 
Telephone (24h): +351911122333 
Fax: +351211122333 
Address: Rua Alexandre Pinto, nº105, 3º esq, 2800-039 Lisbon, Portugal 
Email: PhV@stalapharma.pt 
Country: Portugal 
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2. Pharmacist Material 
 
Pharmacist Checklist 
 
Conditions for dispensing Isotretinoin Generics  
Isotretinoin Generics belongs to the retinoid class of drugs that cause severe birth 
defects. Foetal exposure to Isotretinoin Generics, even for short periods, presents a high 
risk of congenital malformations and miscarriage.  
Isotretinoin Generics is therefore strictly contraindicated in women of childbearing 
potential, unless all conditions in the Isotretinoin Generics Pregnancy Prevention 
Programme are fulfilled. 
If you are aware that a pregnancy occurred in a woman treated with Isotretinoin 
Generics, treatment should be stopped immediately and the woman should be promptly 
referred to the prescribing doctor. 
 
As pharmacist, you should only dispense Isotretinoin Generics after checking the 
following information: 
Table 46 – Pharmacist’s check list  
For women of child-bearing potential: 
The prescription for Isotretinoin Generics is limited to a 30-day supply without 
refills (repeat prescriptions are not permitted) 
 
Prescriptions are dispensed within 7 days of the prescription date. 
(Prescriptions presented more than 7 days after the prescription date should 
be considered expired and the patient should be told to get a new prescription 
from their prescriber) 
 
Ideally, pregnancy testing, issuing a prescription and dispensing Isotretinoin 
Generics should occur on the same day 
 
For men: 
Prescriptions do not have a limit on the duration of treatment to be dispensed 
or restriction on the period the prescription is considered valid. 
 
All patients should be instructed: 
Never to give the Isotretinoin Generics to another person  
To return any unused capsules to their pharmacist at the end of treatment  
Not to donate blood during Isotretinoin Generics therapy and for one month 
after discontinuation due to the potential risk to the foetus of a pregnant 
transfusion recipient  
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3. Patient materials 
 
Patient Information sheet   
 
Isotretinoin Generics belongs to a class of drugs (retinoids) known to seriously damage 
an unborn baby if used in pregnant women. 
Treatment with Isotretinoin Generics during pregnancy is not allowed under any 
circumstances. 
This patient information sheet contains important information about your treatment with 
Isotretinoin Generics and the risk of possible birth defects and miscarriage when taking 
this medicine. 
Before taking Isotretinoin Generics, read this patient information sheet carefully to 
understand important facts about Isotretinoin Generics. 
This guide complements but does not replace the instructions given to you by your doctor 
or pharmacist. 
Further important information about Isotretinoin Generics, including how to take it, 
possible side effects and special warnings, are included in the patient information leaflet 
supplied in each package of Isotretinoin Generics. Please remember to read the package 
leaflet very carefully. 
If you have any questions or concerns about taking Isotretinoin Generics after reading 
this guide, please ask your doctor or pharmacist. 
You will also receive a patient reminder card to care with you at all time to remind you of 
what you need to be aware of and comply with when taking Isotretinoin Generics. 
This medication has been prescribed to you only, do not share it with others and return 
any unused capsules back to the pharmacy. 
 
Information about birth defects 
Women of childbearing potential are not allowed to use Isotretinoin Generics, unless all 
instructions described in this guide are being followed. 
This medicine is likely to seriously damage an unborn baby (i.e. is teratogenic). 
This means that if you take Isotretinoin Generics during pregnancy, even for a short 
period of time, there is a very high risk that your baby will be born with birth defects. 
This diagram represents the possible 
external malformations in the event of 
pregnancy during treatment with 
Isotretinoin Generics: no ear(s) or ears 
attached low down, large head and 
small chin, eye abnormalities, palate 
malformations. Internal malformations 
also frequently occur. These concern 
the heart, the thymus, the nervous 
system, and the parathyroid gland. 
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Before you take Isotretinoin Generics: 
 You must not take Isotretinoin Generics if you are pregnant. 
 You must use effective contraception at for at least one month before beginning 
treatment, during treatment, and for one month after Isotretinoin Generics 
treatment has stopped.  
 As any contraceptive method can fail it is strongly recommended that you use 
two forms of contraception at the same time. However, this does not replace 
the discussion you need to have with your doctor. Your doctor will give you advice 
on the most effective contraception that is appropriate for you, taking into account 
your individual circumstances. 
 You must not become pregnant while taking Isotretinoin Generics, or for 1 
month after stopping treatment as there is an extremely high risk of severe birth 
defects. 
 
Pregnancy testing and monthly prescriptions: 
 You must have at least one negative medically supervised pregnancy test before 
treatment initiation. This is to make sure that you are not already pregnant on 
starting treatment with Isotretinoin Generics. 
 Prescriptions of Isotretinoin Generics will only be for a maximum of 30 days. The 
reason for this is to ensure that you visit your doctor every month to ensure 
that you are following a suitable contraception method and to rule out a possible 
pregnancy. 
 For further prescriptions, you must have a negative medically supervised 
pregnancy test every month.  
 Your doctor will only provide a prescription for Isotretinoin Generics if there is a 
confirmed pregnancy test showing that you are not pregnant. 
 You must agree to follow up visits every month and more pregnancy tests if you 
doctor asks you.  
 You will also have a pregnancy test 5 weeks after stopping treatment. 
 You will only be able to get your Isotretinoin Generics within 7 days from the date 
of the prescription. The pharmacy will not dispense your prescription beyond this 
seven-day deadline. 
 
If there is any possibility you might be pregnant, stop taking Isotretinoin Generics 
immediately and contact your doctor. 
During every monthly visit, your doctor will record the contraceptive methods and 
pregnancy test results in the appointment table included in your patient reminder card. 
Please remember to bring the patient reminder card to every visit! 
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Patient reminder card (including appointment table) 
 
Patient Reminder Card 
Doctor’s name: 
Telephone: 
Isotretinoin Generics belongs to a class of drugs (retinoids) known to seriously damage 
an unborn baby if used in pregnant women. 
Treatment with Isotretinoin Generics during pregnancy is not allowed under any 
circumstances. 
If there is any possibility you might be pregnant, stop taking Isotretinoin Generics 
immediately and contact your doctor. 
Read the package leaflet and Patient information sheet carefully before you start 
treatment. 
If you have any further questions or concerns about taking Isotretinoin Generics, 
talk to your doctor or pharmacist 
 
What you have to do: 
 You must use at least one, but preferably two effective forms of contraception at 
least one month before beginning treatment, during and for 1 month after stopping 
treatment  
 You must not become pregnant while taking Isotretinoin Generics, or for 1 month 
after stopping treatment as there is a an extremely high risk of severe birth defects 
 You must attend monthly follow-up visits and have regular pregnancy testing: 
 - Before treatment initiation you will have to have a pregnancy test, which must be 
negative. 
 - To make sure you are not pregnant during treatment, you must perform monthly 
pregnancy testing 
 - You will have to perform a pregnancy test 5 weeks after completion of treatment  
This medication has been prescribed to you only, do not share it with others and 
return any unused capsules back to the pharmacy. 
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Appointment table 
Please use this table to record the dates of your appointments with your doctor: 
 
Doctor’s name: 
Telephone: 
 
Table 47 – Patient’s Appointment table 
Date of 
appointment 
Contraception 
used 
Pregnancy test 
result* 
Doctor’s 
Signature 
   Positive 
 Negative 
Date:  
 
   Positive 
 Negative 
Date: 
 
   Positive 
 Negative 
Date: 
 
   Positive 
 Negative 
Date:  
 
   Positive 
 Negative 
Date: 
 
   Positive 
 Negative 
Date:  
 
   Positive 
 Negative 
Date: 
 
 
* If pregnancy test is positive, treatment must be stopped immediately and you must be 
urgently referred to a physician specialized or experienced in teratology for advice. 
Have the last pregnancy test requested by your doctor done 5 weeks after stopping 
treatment. 
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4. Discussion/Conclusion 
 
The pharmacovigilance activities have continuously evolved. Initially based mainly on 
the analysis of case reports, effective in detecting serious and rare ADRs, 
pharmacovigilance has evolved into a quality system - based scientific discipline and set 
of activities that include the whole spectrum of evidence relevant to monitoring medicines 
on the market.  
 
The EU pharmacovigilance system embraces this broad scope and is founded on a 
proactive, risk proportionate and above all patient-centered approach to promoting and 
protecting public health. This public health-oriented system is characterized by 
responsiveness to new and emerging safety information, and continual effectiveness 
monitoring in an environment of transparency and openness. The system also strives for 
increased efficiency, by focusing on what works, streamlining processes and reducing 
duplication, with more efficiency efforts to be seen in the coming years. 
 
The evolution of the EU pharmacovigilance system, especially after 2012, has had the 
achievement of better and faster decisions for medicine use as its main goal. Pivotal to 
this is the provision of up-to-date information and warnings to patients.  
 
Pharmacovigilance departments are finding their roles have become increasingly 
strategic. Not only due to higher number of more complex regulatory requirements but 
also the involvement in some high-level business and inter-department activities within 
their own company. This complexity has led to an increase search of outsourcing of PhV-
related services. For most companies, mainly bigger companies (with many associated 
affiliates), delegating part or total PhV activities will become the most cost-effective 
solution.  However, for small or medium-sized companies the monitoring of these 
complex regulations become unsustainable, manely for generics enterprises. 
 
Since the new pharmacovigilance regulations have come into force, any new MA 
application is to include a RMP. This enables the identification of the safety profile of a 
medicine and characterization of the risk induced based on the available data (identified 
risk, potential risk, etc.), to work out the measures to prevent or minimise the risk, and 
the measures necessary to assess the impact of any such minimisation. 
A RMP must be adjusted to the particular product´s needs and to take into account the 
real-life setting, otherwise it may not be successful. 
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The RMP must be accompanied by the adequate PhV/RMMs to prevent or minimize the 
risks in order to promotes an optimal use of the product.  
 
The PRAC is systematically consulted for any new medicine authorised by a centralised 
procedure or for any significant change in existing RMPs. The aim of the PRAC is in 
particular to ascertain the feasibility and the effectiveness of the RMPs. 
 
The PRAC is a key component of the new regulation and community decisions in 
pharmacovigilance. We can see the work developed by the committee in the assessment 
of all aspects of the risk management of isotretinoin. In this case, despite the PPP 
program installed, the exposed pregnancies have continued to occur and the 
recommendations do not seem to have been applied by health care professionals and 
patients. Thus, the PRAC started a review of retinoid medicines in 2016 and in March of 
2018 made a decision and elaborated recommendations, such as the RMM here 
presented. However, the implementation of aRMMs needs to be followed and assessed 
to ensure its effectiveness and if not successful they need to be reassessed. 
 
In the same way, the formal inclusion of patients in spontaneous reports is part of the 
present trend to foster a more proactive pharmacovigilance system. Having more 
information about ADRs by including the medicines end-users can eventually allow for 
the identification of new risks in a given subgroup of patients. However, the spontaneous 
report system has weakness, of which the most important is under-reporting. The under-
reporting delays the detection and identification of safety problems, making it more 
difficult for health authorities to act and preserve public health.  
 
In the future, the EU PVh System must focus on enhancing further the involvement of 
patients and increasing the EU capacity for real-world evidence by harnessing the power 
of technology in using tools offered by healthy services or mobile services. The 
measurement of the effectiveness of risk minimisation measures must become more 
routinely embedded into pharmacovigilance activities. 
 
To summarize, the PhV legislation and its complexity are leading to a high-level burden 
to ensure all the requirements are met and, as we saw by these practical examples, 
these are not always successful. Therefore, one may question the potential need to 
simplify the system in order to have more effective results. 
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